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RIASSUNTO 
Con il termine di Iperfenilalaninemie (HPAs) si intende un 
gruppo di condizioni patologiche genetiche, a trasmissione 
autosomica recessiva. Le HPAs, caratterizzate da elevati 
livelli di L-Fenilalanina (L-Phe) nel sangue, rappresentano 
il più frequente disordine ereditario del metabolismo degli 
amminoacidi (Online Mendelian Inheritance in Man 
database  261600).  Le  HPAs,  con  una  frequenza  di 
1/10.000 nuovi nati, sono dovute a parziale o totale deficit 
dell’enzima  Fenilalanina  Idrossilasi  (PAH).  Questo 
enzima, ad espressione epatica, è responsabile della 
conversione della L-Phe in L-Tirosina (L-Tyr) e richiede 
per il suo corretto funzionamento ossigeno molecolare ed 
il cofattore essenziale tetraidrobiopterina (BH4). I pazienti 
affetti da HPA presentano una ridotta attività di PAH con 
conseguente diminuzione o assenza di conversione della 
L-Phe in L-Tyr. Gli elevati livelli plasmatici di L-Phe, 
insieme con i metaboliti tossici che ne derivano, Fenil- 
Piruvato, Fenil-Lattato e Fenil-Acetato, determinano gravi 
danni cerebrali. I pazienti HPAs non trattati presentano un 
progressivo danno  neurologico,  convulsioni, 
comportamenti simil-autistici, microcefalia, rash cutanei ed 
ipopigmementazione. 
Le HPAs presentano un alto grado di eterogeneità sia da 
un punto di vista genotipico sia per quanto riguarda il 
fenotipo biochimico; in base ai livelli di Phe riscontrati nel 
sangue si possono distinguere 3 classi: 
• Fenilchetonuria   (PKU):   a   questo   gruppo 
appartengono i pazienti con valori ematici di Fenilalanina 
>20mg/dl (>1200µM). Tali valori sono responsabili del 
fenotipo più grave. 
•  Iperfenilalaninemia  di  tipo  II  (HPA  II):  a  questo 
gruppo appartengono pazienti che presentano valori 
ematici  di  Fenilalanina  compresi  tra  10-20mg/dl  (600- 
1200µM); questo corrisponde al fenotipo moderato e viene 
definita anche PKU lieve. 
• Iperfenilalaninemia di tipo III (HPA III): a questo 
gruppo appartengono quei pazienti che presentano valori 
ematici  di  Fenilalanina  compresi  tra  2-10mg/dl  (120- 
600µM);  questa  classe  corrisponde  al  fenotipo  lieve  e 
viene definita anche Iperfenilalaninemia lieve. 
Il gene PAH codificante per la Fenilalanina Idrossilasi si 
trova sul braccio lungo del cromosoma 12 (12q22-q24.1- 
PAH OMIM 261600) è lungo circa 174 kb ed è suddiviso 
in 13 esoni. Mutazioni nel gene PAH causano mancata o 
ridotta  attività  dell’enzima  Fenilalanina Idrossilasi. 
L’enzima è un omotetramero in cui ciascuna subunità è 
costituita da 452 amminoacidi. Ciascun monomero è 
costituito inoltre da tre domini: 
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•  Un dominio regolatorio N-terminale. In seguito al 
legame con la L-Phe, la PAH subisce un cambiamento 
conformazionale che ne determina l’attivazione. 
• Un dominio centrale in cui è localizzato il sito 
catalitico dell’enzima con regioni di legame per il substrato 
L-Phe  e  regioni  di  legame  per  il  cofattore  (Cofactor 
Binding Regions, CBR) BH4, per l’ossigeno e un catione 
Fe 2+. 
• Un  dominio  C-terminale  responsabile  della 
tetramerizzazione della proteina. 
Il gene PAH produce un trascritto maturo di circa 2680 
basi Il database del gene PAH include più di 600 diverse 
mutazioni causative di HPA. Il tipo più frequente è 
rappresentato da mutazioni tipo missense (62%). Le altre 
mutazioni sono meno frequenti (delezioni 14%; splicing 
11%; silenti 6%; non-sense 5%; inserzioni 2%) 
(http://www.pahdb.mcgill.ca).  La  posizione  e  la  natura 
delle mutazioni determinano un diverso effetto sull’attività 
enzimatica da cui spesso deriva l’eterogeneità fenotipica 
della PKU. 
La Fenilalanina Idrossilasi (PAH) è una monoossigenasi a 
funzione mista che catalizza la reazione di idrossilazione 
della L-Phe in posizione 4 usando ossigeno molecolare e 
il cofattore essenziale BH4; nel corso della reazione, la 
BH4 è convertita nella forma ossidata a Quinonoide 
Diidrobiopterina (qBH2). Dalla L-Tyr, tramite vie 
biosintetiche, si ottengono le Catecolamine (Dopamina, 
Adrenalina e Noradrenalina), la Melanina e gli Ormoni 
Tiroidei (Triiodiotiroxina e Tetraiodiotiroxina). L’inadeguata 
attività di PAH determina la diminuzione o l’assenza della 
conversione della L-Phe in L-Tyr. 
Il deficit o la non funzionalità di PAH comporta: 
• l'aumento  della  concentrazione  di  L-Phe  nel 
sangue; 
• l'attivazione di pathway metabolici secondari con 
formazione di metaboliti tossici quali il Fenil-Piruvato, il 
Fenil-Lattato e il Fenil-Acetato. 
Gli aumenti ematici dei livelli di Phe e la mancata 
conversione in Tyr possono determinare danni a livello del 
sistema nervoso centrale attraverso diversi meccanismi: 
•  deficit  di  Tyr:  precursore  delle  Catecolammine, 
degli Ormoni Tiroidei e della Melanina, principale 
pigmento cutaneo. Questo giustifica gli attacchi di 
epilessia e l’ipopigmentazione cutanea spesso 
riscontrati nei soggetti HPAs. 
•  inibizione  della  Piruvato  Decarbossilasi  presente 
nel  sistema  nervoso  centrale  da  parte  dell’acido 
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Fenilipiruvico con conseguente interferenza nella 
formazione della mielina. 
•  competizione  con  il  trasporto  degli  amminoacidi 
neutri (LNA) attraverso la barriera emato-encefalica: 
l'effetto finale potrebbe essere un blocco parziale del 
traffico amminoacidico. Quest’ultimo meccanismo 
sembrerebbe  implicato  nella  patogenesi  molecolare 
del danno cerebrale, infatti l’ingresso nel SNC della L- 
Phe è infatti mediato dal carrier degli aminoacidi neutri 
L-aminoacid trasporter 1 (LAT1). 
Le alte concentrazioni plasmatiche di L-Phe potrebbero 
inibire LAT1 ed impedire il passaggio degli altri aminoacidi 
neutri nel cervello. Inoltre, polimorfismi nel gene che 
codifica per il sistema di trasporto degli LNAA (LAT1), 
potrebbero  giocare  un  ruolo  nel  determinare  la 
suscettibilità al danno cerebrale in soggetti HPAs. In 
definitiva, la discordanza esistente in alcuni pazienti tra 
fenotipo biochimico e clinico potrebbe anche essere 
spiegata dal ruolo svolto dalla BEE per il trasporto di L- 
Phe e dai meccanismi molecolari che determinano questo 
passaggio. 
Inoltre, i bambini affetti da HPAs a causa dei deficit di L- 
Tyr e dei suoi derivati, spesso entro pochi anni dalla 
nascita manifestano sintomi quali ipereccitabilità e crisi 
convulsive che accompagnano il grave ritardo mentale. 
Quindi per prevenire il danno neurologico e le alterazioni 
comportamentali tipiche  dei  soggetti  HPAs  è 
fondamentale che la diagnosi e l’inizio della terapia 
vengano effettuati entro i primi giorni di vita. 
Le HPAs possono essere tenute sotto controllo, infatti, 
mediante una dieta a basso contenuto proteico e quindi di 
L-Phe, con la supplementazione di L-Tyr e di integratori a 
base di miscele amminoacidiche. Attraverso un buon 
controllo delle concentrazioni di L-Phe, soprattutto durante 
la prima infanzia, la maggior parte dei pazienti presenta 
uno sviluppo neurologico e fisico nella norma. Da studi 
recenti è emerso che adulti che abbandonano il regime 
dietetico restrittivo riscontrano anomalie elettrofisiologiche 
del S.N.C. In accordo con questi dati le linee guida 
raccomandano ai pazienti HPAs un trattamento dietetico a 
vita; esso risulta essere estremamente difficile da seguire 
soprattutto in particolari epoche della vita come 
l’adolescenza e la gravidanza. Durante la gravidanza gli 
alti livelli plasmatici di L-Phe attraversano la placenta e 
risultano estremamente tossici e teratogeni per il feto 
determinando una grave embriopatia plurimalformativa 
(Sindrome da PKU materna o MSPKU). La MSPKU è 
lesiva della morfogenesi, nonché dello sviluppo fisico e 
cerebrale del prodotto del concepimento. Il fenotipo clinico 
che   ne   deriva   è   caratterizzato   da   ritardo   mentale, 
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dismorfie facciali, microcefalia, ritardo di crescita 
intrauterino, difetti cardiaci congeniti. 
Poiché la terapia dietetica risulta molto difficile da seguire, 
sono in via di sperimentazione terapie alternative e/o 
integrazioni farmacologiche alla dietoterapia al fine di 
rendere più facile la compliance al trattamento dietetico. 
Alternative terapeutiche  comprendono  la 
somministrazione di BH4 in pazienti responsivi, l’utilizzo di 
aminoacidi  neutri,  la  terapia  enzimatica  sostitutiva  con 
Phe Ammonia Liasi (PAL), la terapia genica, l’utilizzo di 
pluripotent stem cells. 
Una significativa percentuale di pazienti con HPA 
rispondono   alla   somministrazione   di   BH4   con   una 
riduzione significativa della L-Phe sierica. Poiché nella 
stragrande maggioranza dei pazienti HPA il genotipo 
correla con il fenotipo biochimico e clinico, l’analisi 
molecolare del gene PAH è molto importante perché 
contribuisce a confermare o predire il fenotipo biochimico, 
identifica i carriers (in genere asintomatici) e permette 
l’analisi prenatale nelle famiglie ad alto rischio per HPAs. 
Inoltre, l’ampia eterogeneità delle mutazioni a carico del 
gene PAH rende fondamentale definire l’epidemiologia 
molecolare delle mutazioni responsabili sia della PKU che 
della HPA (nei singoli gruppi etnici). 
La diagnosi biochimica delle HPAs si basa sul dosaggio 
delle concentrazioni plasmatiche di L-Phe mediante 
l’utilizzo della spettrometria di massa. La diagnosi 
molecolare di PKU viene effettuata mediante l’analisi 
molecolare del gene codificante la PAH. Tale indagine, in 
Campania,  viene  effettuata presso  i laboratori del 
CEINGE, e prevede tre fasi: estrazione del DNA genomico 
dal campione di sangue conservato in EDTA, 
amplificazione del gene PAH mediante Polymerase Chain 
Reaction (PCR) e suo sequenziamento diretto. 
La diagnosi molecolare delle HPAs contribuisce a 
confermare o predire il fenotipo biochimico dei pazienti 
consentendo loro di intraprendere una terapia appropriata 
e personalizzata. Inoltre attraverso l’analisi molecolare del 
gene PAH è possibile identificare i carriers, in genere 
asintomatici. Nei casi in cui è richiesta, l’analisi molecolare 
del gene PAH permette di effettuare la diagnosi prenatale 
in casi di familiarità per HPAs. 
Durante il periodo del mio lavoro di tesi, ho effettuato 
l’analisi molecolare del gene PAH di pazienti provenienti 
dalla regione Campania. Per effettuare la diagnosi 
molecolare ho utilizzato diverse metodiche di biologia 
molecolare come l’estrazione del DNA genomico, disegno 
e sintesi di primers specifici, reazione di amplificazione 
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PCR ed il sequenziamento diretto secondo il metodo di 
Sanger. 
Sono stati analizzati 390 pazienti HPA del Sud Italia (età 
media   15   anni,   range   2-25   anni,   maschi:   femmine 
rapporto 1.2:1). I pazienti sono stati classificati come 
segue: 121 (15,8%) PKU, 64 (8,4%) HPAII e 205 (26,9%) 
HPAIII. Abbiamo effettuato l'analisi molecolare per la 
rilevazione dello stato di portatore in 373 soggetti. Inoltre, 
abbiamo eseguito la diagnosi prenatale in tre famiglie ad 
alto rischio dal momento che era già presente un figlio 
affetto; l’indagine molecolare ha previsto l’analisi del gene 
PAH nei due genitori e nei villi coriali o negli amniociti 
prelevati alla sedicesima settimana di gestazione. In una 
delle famiglie analizzate, la madre del feto era affetta da 
HPA mentre nel padre non è stata riscontrata alcuna 
mutazione quindi il feto è risultato portatore di una singola 
mutazione. Nelle altre due famiglie analizzate, un feto è 
risultato affetto da HPA in quanto portatore in eterozigosi 
di entrambe le mutazioni dei genitori. L’altro feto è risultato 
non affetto per l’assenza di entrambe le mutazioni presenti 
nei genitori. 
L’analisi molecolare ha permesso di identificare mutazioni 
in 763 su 780 alleli con una detection rate del 97.8%. In 
diciassette pazienti è stata individuata solo una mutazione 
causativa. La mancata identificazione di una mutazione in 
uno dei due alleli può essere dovuta a: 1) alterazioni 
presenti nel promotore o nella regione 3' non tradotta non 
sottoposti a sequenziamento; 2) difetti molecolari negli 
introni; 3) mutazioni all’interno di un enhancer; 4) grandi 
delezioni o duplicazioni. L’analisi ha permesso 
l’identificazione di 103 mutazioni diverse che si 
distribuiscono uniformemente lungo la sequenza del gene 
PAH senza hot spot mutazionali. Delle 103 varianti, 76 
sono mutazioni missense (73%), 19 mutazioni a carico di 
siti di splicing (18,4%), 4 sono delezioni (3,8%) e 4 
mutazioni frame-shift (3,8%). Alcune mutazioni sono state 
trovate con una maggiore frequenza: le mutazioni 
p.R261Q, c.1066-11G> A e p.A403V hanno frequenza 
superiore al 10% (frequenza cumulativa = 24.8); le 
mutazioni p.L48S e p.A300S hanno una frequenza 
compresa tra il 6 ed il 10%, (frequenza cumulativa = 13.6); 
51 mutazioni hanno frequenza compresa tra lo 0,2% ed il 
3,2% (frequenza cumulativa = 56.9); 47 mutazioni sono 
state trovate in un singolo allele con una frequenza dello 
0,1 % (frequenza cumulativa = 4.7). 
L'esone 7 è la regione in cui sono state trovate la maggior 
parte delle mutazioni; infatti esso contiene circa il 23,8% 
delle mutazioni totali (la percentuale aumenta al 33,7% 
considerando solo i pazienti PKU). Inoltre, l’esone 11 
insieme   all'esone   12   contiene   circa   il   34,4%   delle 
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mutazioni totali (la percentuale diventa del 39% 
considerando solo i pazienti HPAIII e del 28% 
considerando i PKU). L’esone 2 contiene l’11,5% delle 
mutazioni totali. Gli esoni rimanenti (1,3,4,5,6,8,9 e 10) 
contengono tra lo 0,4 e l’8,3% del totale delle mutazioni. 
Inoltre, dall’analisi dei nostri pazienti è emerso che circa il 
75% dei pazienti analizzati hanno mutazioni BH4- 
responsive. Infine, in questo lavoro di tesi, tra le mutazioni 
identificate nella popolazione del Sud Italia, 18 sono di 
nuova identificazione (p.E76X, p.I95T, p.I65M, p.N223Y, 
p.Q235X, c.707-2delA, p.R297L, p.Q301P, p.L321I, 
p.W326S, p.F382L, c.1199nt4A>C, c.1315nt20C>T, 
p.K328N, p.N426H, p.I406M, p.Q419R, p.T418I): 14 
missense, 3 di splicing e 1 delezione. 
Attraverso l’analisi del gene PAH diretto, abbiamo 
raggiunto una detection rate del 97.8%. Il nostro studio 
conferma l'eterogeneità delle mutazioni nei pazienti PKU 
anche nella regione Campania e che l'epidemiologia delle 
mutazioni PAH nel Sud Italia si differenzia da quella di altri 
gruppi italiani ed europei. Inoltre, i nostri dati indicano che 
esiste frequentemente una correlazione genotipo-fenotipo. 
In particolare, si conferma che p.R261Q, p.L48S e c.1066- 
11G> A sono più frequentemente associate con la PKU e 
fenotipi   PKU   lievi,   mentre   le   mutazioni   p.A403V   e 
p.E390G sono peculiari dei fenotipi più lievi. 
Nell’ultima   fase   dello   studio,   abbiamo   ottimizzato   e 
validato un protocollo sperimentale per l’analisi dell’intera 
sequenza del gene PAH, incluse le zone regolatorie e gli 
introni, basato su tecnologie di sequenziamento di nuova 
generazione, al fine di identificare mutazioni causative di 
PKU anche in quei pazienti risultati negativi dopo lo 
screening      molecolare      descritto      in      precedenza. 
In conclusione, il nostro studio, ci ha permesso di definire: 
- la causa molecolare alla base delle HPAs nel 98.8% dei 
pazienti, -l'epidemiologia delle mutazioni nel gene PAH nei 
pazienti  del  Sud  Italia,  in  particolare  in  Campania,  -il 
rischio residuo di essere portatori, -la sensibilità al 
trattamento con BH4 dei pazienti affetti da PKU, -la 
correlazione tra alcune mutazioni e fenotipi della malattia. 
Questi dati possono aiutare a ricostruire, da un punto di 
vista storico e antropologico, i vari insediamenti che si 
sono verificati nel nostro paese. 
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SUMMARY 
Hyperphenylalaninemias  (HPAs),  the  most  common 
inborn error of metabolism (1:10.000), is recessively 
inherited and caused by mutations in the gene encoding 
phenylalanine hydroxylase (PAH). PAH converts L- 
Phenylalanine into L-Tyrosine. PAH block results in 
accumulation of L-Phe and toxic metabolites. HPAs is 
classified according Phe serum levels as: 1.Classical PKU 
2.Mild PKU 3.Mild HPA. 
PAH gene, located on chromosome 12, is composed of 171 
Kb  and  13  exons.  To  date  more  than  600  causative 
mutations for PKU are described in the entire PAH gene: 
62% are missense mutations; 14% deletions; 11% splice 
site mutations; 6% nonsense mutations; 2% insertions. 
PAH, hepatic monooxygenase of 452 amino acids that 
catalyzes conversion of L-Phe to L-Tyr using 6R-l-erythro- 
5,6,7,8-tetrahydrobiopterin (BH4) and molecular oxygen. 
PAH consists of three structural domains: 1.N-term 
regulatory domain 2.Large catalytic domain 3.C-term 
tetramerization domain. 
HPA is also the first metabolic disorder in which treatment 
(a Phe-restricted diet) was found to prevent clinical 
symptoms. The aim of my thesis was to perform molecular 
analysis of the PAH gene in 390 PKU patients and 373 
carriers from the Campania Region Screening Center. The 
analysis of PAH mutations allowed to define the molecular 
epidemiology of PAH gene in Campania and compare the 
obtained data with those from other regions of Italy. The 
analysis of the PAH gene have been performed through 
the extraction of genomic DNA from peripheral blood, 
followed by amplification and direct sequencing of the 
entire gene. 
In the last phase of the study, we optimized and validated 
a next generation sequencing protocol for the analysis of 
the entire PAH gene sequence, including introns and 
regulatory regions to identify PKU causative mutations in 
patients negative. 
In conclusion, our study, has allowed us to define: - 
molecular diagnosis of HPA patients achieving a detection 
rate of 98.8%, - epidemiology of mutations in PAH gene of 
patients from Campania, - the residual risk to be carriers, 
and  prenatal diagnosis  in  PKU  family,  -  the 
responsiveness of BH4 in PKU patients, - good correlation 
between mutations and phenotypes of the disease. 
These data may help to reconstruct the historical and 
anthropological point of view, the various settlements that 
have occurred in our country. 
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1. Introduction 
Inborn Errors of Metabolism (IEM) comprise disorders in 
which a single gene defect causes a clinically significant 
block in a metabolic pathway resulting either in 
accumulation of substrate behind the block or deficiency 
of the product. All IEMs are all genetically transmitted 
typically in an autosomal recessive or X-linked recessive 
fashion. The major categories are: 
 Organic    acidemias    (e.g.,    methylmalonic    or 
propionic acidemia,  multiple  carboxylase 
deficiency) are caused by abnormal metabolism of 
proteins, fats or carbohydrate. 
 Fatty acid oxidation defects (e.g., short, medium, 
and long- chain acyl-CoA dehydrogenase 
deficiencies) also known as Beta-oxidation defects, 
are a distinct type of organic acid disorder. 
 Primary      Lactic      Acidoses      (e.g.,      pyruvate 
dehydrogenase, pyruvate carboxylase and 
cytochrome oxidase deficiencies) present with 
severe lactic acidosis. 
 Urea  cycle  defects  (e.g.,  citrullinemia,  ornithine 
transcarbamylase deficiency, and arginosuccinic 
aciduria). 
 Disorders    of    carbohydrate    metabolism    (e.g., 
galactosemia, hereditary fructose intolerance, 
fructose 1,6-diphosphatase deficiency and the 
glycogen storage diseases) are a heterogeneous 
group caused by inability to metabolize specific 
sugars, aberrant glycogen synthesis, or disorders 
of gluconeogenesis. 
 Lysosomal          storage          disorders          (e.g., 
mucopolysaccharidosis, Tay-Sachs, Niemann-Pick 
disease, Gaucher’s disease) are caused by 
accumulation of glycoproteins, glycolipids, or 
glycosaminoglycans within lysosomes in various 
tissues. 
 Peroxisomal  disorders  (e.g.,  Zellweger  syndrome 
and neonatal adrenoleukodystrophy) result from 
failure of the peroxisomal enzymes. 
 Aminoacidopathies        (e.g.,        phenylketonuria, 
hereditary tyrosinemia, nonketotic 
 hyperglycinemia,    maple    syrup    urine    disease 
[MSUD] and    homocystinuria)    are    a    very 
heterogeneous group ofdisorders. 
Phenylketonuria (PKU) is an Inborn Error of Metabolism in 
which the normal conversion of the dietary amino acid L- 
phenylalanine (L-Phe) to tyrosine is blocked. The resulting 
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build-up of phenylalanine and its metabolites in young 
patients produces a number of severe effects including 
intellectual impairment and cutaneous changes. 
 
 
 
 
1.1 Hyperphenylalaninemias 
Hyperphenylalaninemias (HPAs) are a group of inherited 
diseases due to the defective phenylalanine hydroxylase 
(PAH) activity resulting in accumulation of phenylalanine 
in blood and other tissues. The mean frequency of HPAs 
is 1:10.000 in Caucasian population, in most cases (98% 
of subjects), HPAs result from mutations in the 
phenylalanine hydroxylase gene (20). Human 
phenylalanine hydroxylase (PAH) converts the essential 
amino acid L-Phe into L-tyrosine (L-Tyr), essential for the 
synthesis of important neurotransmitters like dopamine, 
epinephrine, nor-epinephrine and melanin (28). L-Phe is 
an essential amino acid present in the various proteins 
contained in the diet. Normally, a small L-Phe amount is 
used for protein synthesis; the remainder is hydroxylated 
to L-tyrosine, which is used for synthesis of protein and 
several  compounds  or  is  degraded  to  produce  energy. 
The hydroxylation of phenylalanine requires phenylalanine 
hydroxylase (PAH) enzyme, (6R)-L-erythro-5,6,7,8- 
tetrahydrobiopterin (BH4) cofactor, and molecular oxygen 
(22, 29). The catalysis by this iron-dependent enzyme is 
the major pathway for catabolic degradation of dietary L- 
Phe and accounts for approximately 75% of the L-Phe 
disposal (34). The autosomal recessive disorder PKU is 
the result of a deficiency of PAH enzymatic activity. When 
the conversion of L-Phe to L-tyrosine is blocked, L-Phe 
accumulates in body fluids or is converted to other 
metabolites toxic for the central nervous system (5). 
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defect can result in a variety of cutaneous abnormalities, 
including diffuse hypo-pigmentation, eczema and 
photosensitivity (5). These cutaneous changes may result 
from the toxic effects of L-Phe and its decomposition 
products in the skin. However, the clinical picture includes 
delayed psychomotor development, mental retardation, 
mousy odour in the urine, irritability, light cutaneous 
pigmentation,  eczema,  and  epilepsy.  Among  PKU 
patients, a remarkably wide variation is observed in both 
clinical manifestation and therapeutic response (5). 
 
 
 
 
1.2 PAH Protein 
(PAH: EC 1.14.16.1). PAH is a hepatic monooxygenase 
that catalyses the conversion of L-Phe to L-Tyr using 6R-l- 
erythro-5,6,7,8-tetrahydrobiopterin (BH4) as a coenzyme. 
PAH consists of three structural and functional domains: 
 N-terminal regulatory domain (residues 1-142), 
 Large catalytic domain (residues 143-410), 
 Small C-terminal tetramerization domain (residues 
411-452) (Figs. 2 and 4). 
The tetramer model is a dimer of two conformationally 
different dimers, and its dimensions are of about 85 Å × 
100 Å × 75 Å (5, 6) (Fig.2): 
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Fig. 2: Scheme showing the secondary structure 
assignment of human Phenylalanine Hydroxylase 
sequence (SWISS-PROT P00439). 
 
 
 
 
The regulatory domain of PAH contains an α-β sandwich 
with an interlocking double βαβ motif (Fig 3). The N- 
terminal autoregulatory sequence (ARS; residues 19–33) 
extends over the active site in the catalytic domain. A key 
residue in the regulation of this enzyme is the serine 16, 
phosphorylated by the cAMP-dependent protein kinase 
(PKA). Although L-Phe is the primary factor in the 
activation of PAH, phosphorylation mediates the enzyme 
reaction  by  decreasing  the  substrate  concentration 
required to activate PAH (20, 28). 
The catalytic domain has a basket-like arrangement 
composed of 12 α-helices (45%) and 6 β-strands (16%). 
The active site is located in the center of the catalytic 
domain (18). Adjacent to the active site is a channel that 
may provide substrate access to the active site (Fig. 3). As 
isolated, the PAH contains a Fe (III) ion in the active site 
(34), coordinated to His285, His290 and Glu330. Both 
His285 and His290 have been shown by site-directed 
mutagenesis to be required for iron binding (23). A set of 
27 amino acids (His 263 to His 289) forms a region that 
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was thought to be responsible for BH4 binding (29). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: Structure of a monomer of human Phenylalanine 
Hydroxylase full-length composite model. In figure are 
shown the regulatory domain (residues 19–142), the 
catalytic domain (residues 143–410) and the 
tetramerization domain. 
 
 
 
 
The  tetramerization  domain,  consisting  of  a  C-terminal 
arm, contains two antiparallel β-strands, forming a β-sheet 
(the dimerization motif), and α-helix (the tetramerization 
motif) (Fig. 3). The crystal structure of PAH has revealed 
that  the  tetrameric  oligomers  are  dimers  of  dimers  in 
which the interaction between the two dimers is mediated 
by the C-terminal ‘arm’. The tetrameric and dimeric forms 
of PAH are in equilibrium and have different catalytic 
properties because the tetramer, but not the dimer, 
demonstrates a positive kinetic cooperativity with respect 
to L-Phe. In particular, substrate activation results in 
conformational changes involving the tertiary as well as 
the quaternary structure and drives the tetramer–dimer 
equilibrium toward the tetrameric form (9). 
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Fig. 4: Structure of a tetramer of human Phenylalanine 
Hydroxylase full-lengtht. The monomers interact through 
the tetramerization domain. 
 
 
 
 
1.3 Catabolic Pathway of Phenylalanine 
The L-Phe amino acid is hydroxylated by the enzyme PAH 
to form Tyr; the PAH is a mixed function monooxygenase 
which catalyzes the hydroxylation reaction of the L-Phe at 
position 4 using molecular O2 and the essential cofactor 
BH4 (Fig.5); in the course of the reaction, the BH4 is 
converted into the oxidized form to Quinonoide 
dihydrobiopterin (QBH2). The cofactor is regenerated by 
the action of the enzyme dihydropteridine reductase 
(DHPR) that uses NADPH as a source of reducing power. 
Tyr,  via  secondary  biosynthetic  pathways,  is  then 
converted in several products: catecholamines (dopamine, 
adrenaline and noradrenaline), melanin and thyroid 
hormones. The inadequate activity of PAH determines the 
decrease or absence of the conversion of L-Phe in L-Tyr 
(5, 16). 
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Fig. 5: Normal Phenylalanine Metabolism. 
 
 
The deficit or non-functionality of PAH involves: 
• The increase of blood L-Phe; 
• The activation of secondary metabolic pathways 
with the formation of toxic metabolites such as phenyl- 
pyruvate, lactate and the phenyl-acetate (Fig. 6). 
  
 
Fig. 6: Alterated Phenylalanine metabolism. The inhibition 
of Phenylalanine Hydrolase leads to the accumulation of 
Phenylalanine and of toxic metabolites. 
 
 
 
1.4 Pathophysiology of Phenylketonuria 
The increased levels of L-Phe in blood can cause damage 
in  the  central  nervous system  through  several 
mechanisms: 
 Tyr    deficiency,    which    is    the    precursor    of 
catecholamines,  thyroid  hormones  and  melanin. 
This justifies the attacks of epilepsy and skin hypo- 
pigmentation often seen in PKU patients. 
 Inhibition of pyruvate decarboxylase in the central 
nervous system by acid Phenyl-piruvic; it interferes 
with the myelin formation (5). 
 Competition  with  the  transport  of  neutral  amino 
acids through the blood-brain barrier: the final effect 
may be a partial blockage of the amino acid traffic. 
 Albeit    not    yet    completely    clear,    the    latter 
mechanism would seem implicated in the 
pathogenesis of brain damage from PKU. From a 
molecular point of view, the L-Phe entry into the 
CNS is mediated by the carrier of the neutral amino 
acids (L-aminoacid transporter 1-LAT1). 
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Two other neutral amino acids, L-Tyr and L-Typtophan, 
are transported into the brain through the same carrier 
LAT1.  The  high  plasma  concentrations  of  L-Phe  may 
inhibit and prevent the passage of the other neutral amino 
acids in the brain. This will lead to a dysfunction of 
neurotransmitters (30). 
In addition, polymorphisms in the gene encoding for the 
LNAA transport system (LAT1) may play a role in 
determining the susceptibility to cerebral damage in PKU. 
Ultimately, the discrepancy that exists in some patients 
between clinical and biochemical phenotype could also be 
explained by the role played by BEE in the transport of L- 
Phe. 
In addition, children with PKU, because of the lack of Tyr 
and its derivatives, often within a few years after the birth, 
have symptoms such as hyperexcitability. To prevent 
neurological  damage  and  behavioural  changes  is 
essential that diagnosis and therapy are carried out within 
the first few days of life. 
 
 
 
 
1.5 Phenylalanine Hydroxylase Gene 
The PAH gene is located on the long (q) arm of 
chromosome 12 between positions 22 and 24.2. More 
precisely,  the  PAH  gene  is  located  from  base  pair 
103,232,103 to base pair 103,311,380 on chromosome 
12. The Human PAH gene is composed of 171 Kb 
organized into 13 exons. The full-length PAH cDNA 
(GenBank cDNA Reference Sequence U 49897) encodes 
a protein of 452 amino acids (about 52 kDa for each 
subunit). 
 
 
 
Fig 7: Cytogenetic Location of Phenylalanine Hydroxylase 
gene: 12q22-q24.2. Molecular Location on chromosome 
12 
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1.6 Causative mutations 
To date more than 600 causative mutations for PKU have 
been described in the entire PAH gene. 
The pathogenic mutations in the PAH gene of PKU patients 
were identified after the cloning of the gene in 1983. 
Subsequently, the ‘Phenylalanine Hydroxylase Locus 
Knowledgebase’ PAHdb was generated and curated at 
McGill University (http://www.pahdb.mcgill.ca/); in this way, 
the mutations and the variants present in PAH gene are 
catalogued together with different information about PAH 
alleles and mutations; in fact,  clinicians and laboratories 
from around the world report in this database the features of 
all mutations. In the ‘Phenylalanine Hydroxylase Locus 
Knowledgebase’ PAHdb database at this time are present 
more than 600 PAH mutations identified world wide. 
Furthermore, in the database are listed the notices about 
the nucleotide alterations as the in vitro residual enzyme 
activities of about 200 mutations. 
Of the 600 mutations: 
•  60.5% are missense mutations; 
•  13.5% deletions; 
•  11% splice site mutations; 
•  5% nonsense mutations; 
•  1.8% insertions. 
Most of the PAH mutations are missense mutations that not 
avoiding transcription or translation. The majority of the 
patients are compound heterozygotes (10, 12, 13, 14, 24, 
25, 26, 50, 51). The nature and the position in the gene of 
the mutation determines the effect on the structural, 
biochemical and biophysical properties of the PAH as the 
enzymatic activity which correlates with the phenotype of 
the patient. 
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Fig. 8: Mutation map of Phenylalaine Hydroxylase gene. In 
figure are reported causative mutations described until 
August 2007. 
 
 
 
1.7 Genotype-Phenotype correlation 
In 1998 Guldberg at al. identified the complete genotype in 
686 patients from 7 European centers. Based on the L- 
Phe tolerance of 297 functionally hemizygous patients 
(patients carrying a null allele and the uncharacterized 
mutant allele), an arbitrary phenotype class was assigned 
to each mutations for which the residual enzyme activity 
was not known. In 79% of the analyzed patients, the 
predicted phenotype tallied with the observed phenotype. 
Moreover,  this  study  led  to  the  conclusion  that  the 
genotype is the main determinant of the biochemical 
phenotype in most PKU patients. Many studies reported 
genotype/phenotype correlations in different populations 
(12,  13,  14,  24,  25,  26,  50,  51);  some  publications 
reported also inconsistencies, i.e. genotypes associated 
with several different phenotypes. Numerous studies 
reported that the combination of the two mutant alleles is 
important for the residual PAH enzyme activity. In fact, 
PAH enzyme, being a homotetramer, consists of 
arrangements of different mutant monomers and its 
residual activity is not simply the mean of each subunit 
activity   (9).   However,   there   is   a   highly   significant 
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correlation between the genotype and the biochemical 
phenotype of the patients although the genotype is 
expressed as the predicted residual enzymatic activity of 
the patient and calculated as the mean of the combined in 
vitro residual enzyme activities of both mutant alleles. 
In the population of Campania, genotype–phenotype 
analysis in compound heterozygous patients was 
performed according with the ‘quasi-dominant’ theory of 
Guldberg et al. (26), in which the milder mutation between 
the two mutations influences the outcome of phenotype. 
This simple method predicted a correct correlation 
genotype and phenotype in 76% of Campania cases. In 
the remaining patients, there was discordance between 
genotype and phenotype. In addition to our data, several 
other studies have reported inconsistencies between 
genotype–phenotype (12, 13, 14). Different factors may 
contribute to this discrepancy: possible phenotypic 
misclassifications, incorrect tolerance assessment, the 
unpredictable result of allelic complementation in 
heterozygous patients, and the role of modifier genes, 
including cellular quality control systems (15, 19, 42). 
 
 
 
 
1.8 Responsiveness to BH4 
A pilot study in the United States demonstrated that many 
patients with PKU respond to an oral loading dose of 10 
mg/kg BH4 (43). The clinical trial was performed on 37 
PKU patients, 20 females and 17 males, including 5 
children ages 5–14 years who participated. Twenty-four 
patients were classical or severe PKU (blood Phe >1200 
µmol/L), 10 had atypical or mild PKU (blood Phe 360– 
1199  µmol/L),  and  3  had  mild  HPA  (blood  Phe  <360 
µmol/L). Today, the responsiveness to BH4 administration 
in PKU is defined as a decrease of L-Phe in serum of 
more than 30% of the value before the BH4 challenge 
(20mg/kg body weight), within approximately 24h post- 
load.  Furthermore,  BH4  deficiency  should  be  excluded 
and pathologic PAH mutations should be identified. 
However, in literature BH4-responsiveness has been 
assessed in different ways (1, 3). Newborns are usually 
tested using the standard BH4 loading test. In few cases a 
BH4 treatment trial was performed. BH4-responsiveness 
is different among patients with different genotypes (3). In 
some BH4-responsive patients, L-Phe levels decrease 
significantly, but do not reach physiologic concentrations. 
In addition, different PAH mutations have been studied in 
vitro by expression analysis, resulting in expression of 
mutant PAH protein with different residual enzymatic 
activity (9, 12). BH4-responsive PAH mutations are listed 
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elsewhere (http://www. bh4.org/biopku.html). It was 
reported   that   residual   PAH   activity   (in   vivo)   is   a 
prerequisite for BH4-responsiveness; on the other hand, 
mutations, causing severe structural changes (truncation) 
in the expressed protein and with undetectable PAH 
activity, are not expected to be stimulated by BH4. 
However, in vitro expression of mutant PAH protein with 
residual activity does not guarantee BH4–responsiveness. 
Different hypotheses have been proposed for explaining 
BH4 responsiveness (4, 17, 45): 
1) PAH mutant enzymes have a reduced binding 
affinity for BH4, which can be surmounted at 
increased BH4 concentrations; 
2) BH4 may stabilize PAH by protecting the protein 
against proteolytic cleavage or degradation, as a 
chaperon; 
3) BH4 helps stabilize PAH mRNA, and 
4) BH4 contributes to regulation of PAH gene 
expression (18, 44, 4). However, it has been 
indicated that BH4 influences the conformational 
stability of PAH and also its activity (46). 
 
 
 
 
1.9 Molecular genetic testing 
Clinical testing: targeted mutation analysis. A panel of 1– 
15 more common point mutations and very small deletions 
have a detection rate of approximately 30–50%. Alleles 
may be population related (40). 
Mutation scanning: with this technology it is virtually 
possible to indentify all point mutations in the entire PAH 
gene. Mutation scanning by denaturing high performance 
liquid chromatography, a fast and very efficient method to 
detect locus-specific point mutations, has shown its 
relevance for detection of the pathologic alleles of PKU 
(40). 
Duplication/deletion analysis: comparative multiplex 
dosage analysis is helpful to detect large duplications or 
deletions in the rare cases in which no mutations have 
been detected. This technique has been successfully 
utilized to identify abnormal dosage in 20% of 
uncharacterized  PKU  mutations  and therefore, 
duplications and/or deletions may account for up to 3% of 
mutations (40). 
Linkage analysis: in families at high risk for PKU in which 
only one or neither PAH allele has been identified, linkage 
analysis may be an option for carrier testing and prenatal 
diagnosis. Linkage studies are based on accurate genetic 
counselling and clinical diagnosis of HPA in the affected 
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family member(s) and accurate understanding of the 
genetic relationships in the family. To carry out a linkage 
analysis it needs to obtain samples from multiple family 
members, including that from at least one affected 
individual. The markers (STR and VNTR) used for linkage 
analysis are highly informative because they are both 
intragenic and flanking to the PAH locus; thus, they can be 
used with 99% accuracy in PKU families (7). 
Direct DNA sequencing: this is a routine procedure that in 
specialized clinical laboratories permits the discovery of 
disease-causing genes and underlying mutations. Single 
nucleotide substitutions leading to amino acid changes 
(missense mutations), translation stop signals (nonsense 
mutations), or aberrant exon/intron splicing, responsible 
for most disease-causing alterations of genes can be 
detect with a mutation detection rate of about 97% (13, 
14). 
Next  Generation Sequencing:  novel  sequencing 
technology featured by high productivity and sensitivity in 
mutations detection. Their application to the study of the 
molecular basis of several human inherited diseases has 
demonstrated the effectiveness of the massively parallel 
sequencing approaches in generating high-quality data 
(20b). Recent findings also showed the quantitative nature 
of  PCR amplification/high  throughput  sequencing 
approach and its ability in the simultaneous detection of 
both SNPs and CNVs in target genes, thus increasing the 
spectrum of detected variations (>99.5%) (25b). 
 
 
 
 
1.10 Functional Test 
To date, more than 600 gene variants have been identified 
in the PAH gene that contains 13 exons spread over 80 
kb. The majority of PAH mutations are correlated to a 
specific biochemical/metabolic phenotype. For example, 
some “mild” PAH mutations reduce the affinity of the 
enzyme for the substrate Phe, other reduce the affinity of 
the enzyme for the BH4, other mutations cause instability 
of the structure of the enzyme. Data regarding the 
phenotypic impact of some mutations are either lacking or 
controversial (http://www.pahdb.mcgill.ca). This is 
particularly the case of mutations of new identification, 
because of the lack of functional analyses. To study the 
effects of mutations on PAH activity, the most reliable 
possibility is to perform expression studies using wild-type 
and mutant cDNA to evaluate the enzymatic activity of the 
PAH proteins. It is possible, for example, to measure the 
14C radiolabeled L-Phe converted to L-Tyr. The residual 
activities  of  the  mutant  PAH  enzymes  can  be  then 
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estimated as the percentage of wild-type enzyme activity. 
 
 
 
 
1.11 Prenatal diagnosis 
Information of molecular diagnosis has helped families of 
HPA to decide different opinions to continue pregnancy. 
Prenatal diagnosis in families at high risk permits an early 
genotype characterization allowing the prognosis of PAH 
deficiency. The molecular analysis of the PAH gene is 
conducted in both parents and in chorionic villi or 
amniocytes taken at the sixteenth week of gestation. 
Sequencing of PAH gene permits the elucidation of 
mutations causing HPAs. The analysis is performed on 
amniotic   cells   obtained   at   16th   week   of   gestation. 
Previous procedures for prenatal diagnosis and carrier 
screening for PKU have been based on the assessment of 
different RFLPs within the PAH gene, with a 30% of 
informativity in Chinese and Japanese PKU families and 
with a 80% of informativity in Caucasian PKU families. 
Successively, has been added VNTR system increasing 
the informativity level to 90%. Mutation detection in HPA 
disorder by PCR and direct sequencing of the 13 specific 
exons is a good diagnostic method. In addition, for the 
prenatal molecular diagnosis has advantages that it can 
be performed earlier, quicker and leads to an accurate 
diagnosis in a very short time. Finally, mutation analysis is 
a useful method for prenatal diagnosis, when the disease- 
causing mutations have been identified in the proband and 
ideally also confirmed in the parents. 
 
 
 
 
1.12 PKU maternal Syndrome 
In 1956, Charles Dent has been one of the first physicians 
to identify the teratogenic effects of maternal L-Phe on the 
foetus. These effects include mental retardation, facial 
dysmorphism, microcephaly,  intrauterine  growth 
retardation (IUGR), developmental delay and congenital 
heart disease (CHD) (31). In untreated PKU pregnancies 
with L-Phe levels ≥1200 µmol/l, more than 90% of the 
offspring have microcephaly and mental retardation, 40% 
have IUGR and 12 to 15% have CHD. 
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Fig.   9:   The   newborn   suffering   from   maternal   PKU 
syndrome. 
 
 
The teratogenic effects are less recurrent when L-Phe is 
between 600 and 1200 µmol/l; in addition, when dietary 
treatment  lowers  the  blood  L-Phe  level  to  120  to  360 
µmol/l, the offspring may be normal. Then there is a dose- 
response relation. The most important way to prevent 
teratogenic effects on the developing foetus is a good 
metabolic state achieved before conception. However, it is 
still advantageous to the foetus to decrease L-Phe levels 
within the first trimester in case of an unexpected 
pregnancy. Recently, it was suggest that fluctuations of L- 
Phe serum levels have significant impact on the offspring 
neuropsychometric outcome. However, few cases of 
untreated or poorly treated PKU pregnancies result in 
normal offspring, while some apparently well-treated 
pregnancies are not successful. The precise mechanism 
remains unclear. 
 
 
 
 
1.13 Therapy 
Conventional diet:  worldwide, PKU diagnosis is performed 
in newborn screening programs, because a low-Phe diet 
is started early, mental retardation can be prevented (2, 
33, 48). Difference in L-Phe tolerance is related not only to 
metabolic status but also to genetic background and to 
general health situation. Physical activity, growth, 
pregnancy, and infections may alter the needs for Phe. 
Therefore, the diet must be standardized for each patient 
so that: 
1)   Phe   and  its  metabolites   do   not   reach   toxic 
concentrations 
2) Intake of other amino acids must be adequate to 
provide the patient’s metabolic needs. 
The PKU diet composition has modified very little since its 
introduction in the 1950s; in fact, it is a low-protein diet 
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supplemented  with  a  Phe-free  mixture  of  amino  acids, 
plus added minerals, vitamins and other nutrients. PKU 
diet   is   extremely   restrictive   and   difficult   to   follow. 
Moreover, the Phe-free mixtures of amino acids have an 
unpleasant flavor and smell and must be consumed in 
relatively large amounts. The quality of life under the PKU 
diet is severely compromised. Therefore, alternatives to 
the PKU diet have been actively sought. 
Nutritional  deficiencies:   The  PKU  patient  management 
seeks to optimize the growth, the development, and the 
dietary compliance (33). In fact, the limitation of Phe 
determines many nutritional problems: the quality of the 
available amino acid integration, the neurotrophic and 
neuroprotective effects of added long-chain 
polyunsaturated fatty acids (LCPUFA), micronutrient 
deficiencies, bone disease, and antioxidant status. Then, 
the nutritional status of PKU patients should be regularly 
checked. Furthermore, a further benefit of BH4 
supplementation is that it may reduce some of the 
nutritional deficits by increasing the natural protein intake. 
Adequate   calcium   and   vitamin   D   integration   is   an 
important component of care. In addition, a vitamin B12 
deficiency can occur when PKU patients rest the diet in 
adolescence. Finally,  some  of  the  PKU 
neuropsychological problems may be due to a deficiency 
of the amino acid Tyr. Furthermore, PKU subjects have to 
avoid aspartame, an artificial sweetener containing Phe. 
 
 
Therapies under investigation 
1.  BH4  supplementation:   There  is  debate  in  literature 
regarding the helpfulness of BH4 supplementation in 
patients bearing of some specific mutations or genotypes 
(27, 32). In fact, a relevant number of PKU patients show 
reduced plasma Phe levels after a BH4 loading test then, 
in these patients, an important alternative to diet is based 
on the BH4 supplementation. In fact, about 60% of the 
patients with plasma Phe levels between 400 and 800 
µmol/L respond to the BH4. However, some patients with 
higher Phe levels also respond to BH4 therapy. A few 
hours after BH4 administration, blood Phe concentrations 
decrease  considerably  (1,  3,  44,  38).  Nevertheless,  a 
large group of patients with PAH mutations do respond to 
treatment with BH4 (3, 32, 36). Furthermore, it has been 
shown that long-term BH4 treatment may also raise the 
Phe tolerance in a lot of patients with severe PKU 
phenotype (27). In addition, it has been hypothesized that 
supplementation with BH4 combined with the diet would 
be sufficient also for the prevention of the maternal PKU 
syndrome (47). 
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In addition to gene therapy, some studies with PAH 
expression  in  tissues other than  liver have  been 
developed for PKU. Epidermal keratinocytes and dermal 
fibroblasts were infected with retroviral vectors expressing 
PAH and/or GTP-cyclohydrolase (one of the enzymes 
involved in BH4 synthesis) gene obtaining high Phe 
clearance (11). 
5. Therapies under investigation: different attempts have 
been performed to find other effective treatment modalities 
for PKU. Glycomacropeptide (GMP) is a low Phe protein 
derived from cheese. Recently, has been reported 
improved nutritional management of PKU by using a diet 
with GMP, if compared with conventional amino acid 
formulas. GMP may represent an alternative safe therapy 
in the nutritional management of PKU (2). 
6. Somatic gene therapy: this approach it is being tested 
in animal models and is promising as a potential treatment 
(11). 
7. Induced pluripotent stem cells: hepatocyte or 
hematopoietic stem-cell transplanted with normal PAH 
cDNA and liver repopulation with these cells, represent a 
further treatment approach under investigation. In an 
animal model, this approach has effectively correct HPA 
phenotype (2). 
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2. Aim of the thesis 
Molecular analysis of the PAH gene is useful for several 
reasons: 
1.  Identification of PAH mutations. 
2.  Identification of PKU carriers (usually 
asymptomatic). 
3.  Prenatal diagnosis for the pregnancies at high risk. 
4.  Prediction of the biochemical phenotype. 
5.  Identification of BH4-sensitive mutations that may 
lead to a patient-rational treatment. 
6.  Sequencing  of  the  entire  PAH  gene  (including 
22000 bp at the 5’ end of the transcription start site, 
exon regions, intron regions and 1000 bp at the 3’ 
end). 
 
 
Moreover, due to the wide heterogeneity of mutations in 
the PAH gene, it makes essential to define the molecular 
epidemiology of the mutations responsible for both PKU 
and HPA patients (in individual ethnic groups). 
 
 
The aim of my thesis work was to perform molecular 
analysis of the PAH gene in 390 PKU patients and 373 
carriers that come from the Campania Region Screening 
Center ASL 1. The analysis of PAH mutations allowed to 
define  the  molecular  epidemiology  of  mutations  in  the 
PAH gene in Campania and compare the obtained data 
with those from other regions of Italy (Southern Italy, i.e. 
Calabria, Sicilia, Puglia and Basilicata, Northern Italy; i.e. 
Piemonte) and Europe (Spain and Portugal). 
 
 
An additional aim of the present thesis was to develop and 
validate a diagnostic approach, based on next generation 
sequencing (NGS), able to identify novel causing-disease 
mutations in PAH patients with undetermined alleles, thus 
increasing our detection rate and improving our ability to 
achieve a genetically based etiologic diagnosis of PAH. 
38 
 
 
39 
 
3. Materials and methods 
3.1 Patients 
We studied 390 Caucasian HPA unrelated patients from 
Southern Italy (98% from the Campania region; median 
age 15 years, range 2–25 years; male:female ratio 1.2:1). 
Moreover, we performed the molecular analysis for the 
detection of carrier status in 373 subjects. 
Patients were classified on the basis of pre-treatment 
plasma Phe concentrations and Phe tolerance into HPAI 
or ‘classic PKU’ (pre-treatment Phe levels > 1200 mmol/L, 
Phe tolerance: 250–350 mg/L); HPAII (pre-treatment Phe 
levels in the range 600–1200 mmol/L, Phe tolerance: 350– 
600 mg/L); HPAIII (pre-treatment Phe levels < 600 mmol/L, 
Phe tolerance: > 600 mg/L). The HPAIII category included  
five patients whose Phe levels were < 360 mmol/L under a 
Phe unrestricted diet. Tolerance was defined in patients > 
2 years of age as the highest Phe intake that was able to 
maintain plasma Phe levels within the safe range (120–
360 mmol/L). In the case of discrepancies between pre-
treatment plasma Phe concentrations and Phe tolerance, 
the phenotypic class was assigned  according  to  Phe  
tolerance data. 390 patients were identified by a neonatal 
screening program and two patients who were born in the 
pre-screening era were diagnosed after the identification of 
mental retardation. 
The patients were classified: 121 (15.8%) PKU, 64 (8.4%) 
HPAII and 205 (26.9%) HPAIII 
The parents of each patient were informed about the aims, 
methods and possible results of DNA analysis and they 
gave the informed consent to the study. 
 
 
3.2 Prenatal diagnosis 
We performed the prenatal diagnosis in three families at 
high risk for HPA. Amniotic cells or corionic villi of the feti 
were obtained at 16th week of gestation, tripsinized, 
washed and centrifuged. The obtained pellets were used 
for genomic DNA extraction. Contamination of maternal 
material in amniotic fluid has been excluded through 
methods based on DNA polymorphisms by analysis of 
polymorphisms in the human genome repeat (STR). The 
sixteen  STRs  used  for  the  survey  are  listed  in  the 
following Table: 
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 STR Cromosom 
1 D8S1179 8 
2 D21S11 21q11.2-q21 
3 D7S820 7q 
4 CSF1PO 5q33.3-34 
5 D3S1358 3p 
6 THO1 11p15.5 
7 D13S317 13q22-31 
8 D16S539 16q24-qter 
9 D2S1338 2q35-37.1 
10 D19S433 19q12-13.1 
11 vWA 12p12-pter 
12 TPOX 2p23-2pter 
13 D18S51 18q21.3 
14 D5S818 5q21-31 
15 FGA 4q28 
16 Amel X, Y 
 
 
Successively, the genomic DNA was used for the 
amplification reaction (PCR) and finally for the direct 
sequencing of the 13 exons of PAH gene. 
 
 
3.3 DNA extraction and quantification 
A blood sample (1 mL) was collected by venipuncture in 
EDTA (ethylene-diamine-tetra-acetate). The genomic DNA 
was extracted from white blood cells, after cell lysis and 
deproteinization using sodium perchlorate by the 
commercial kit “Nucleon BACC2” of the Amersham Life 
Science. For each sample, the extracted DNA was 
quantified by spectrophotometric reading at 260nm. The 
quality of the extraction was evaluated by checking the 
relationship between the reading at 260nm and 280nm 
(optimal ratio ≥1.8). DNA samples were prepared in the 
work concentration of 60 ng/µl. 
 
 
3.4 PCR 
All coding regions and exon-flanking intronic sequence of 
the  PAH  gene  of  each  DNA  sample  was  analyzed  by 
PCR, with which were amplified all the coding regions of 
the PAH gene. The PCR products are monitored by 
electrophoretic analysis on agarose gel at 1.5% and 
subsequently analyzed by direct sequencing. The PCR 
reaction  is  carried  out  in  a  final  volume  of  50  l  on 
Thermal   Cycler   2720   of   "Applied   Biosystems".   The 
protocol   used   is   the   "Touchdown",   with   which   the 
annealing temperature is progressively lowered by 0.5 ° C 
at each cycle, so that at the beginning the primers anneal 
only with sequences perfectly complementary. The 
reactions of chain polymerization were carried out using 
the amplification conditions summarized in Table 1 The 
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optimal program for the PCR amplification is summarized 
in Table 2. 
 
 
 
 
Reagent Initial 
Concentration 
Final 
Concentration 
PCR Buffer 10x 1x 
MgCl2 25mM 1.5 mM 
dNTPs 2.5 mM 100 µM 
Oligo Forward 15µM 0.6 µM 
Oligo Reverse 15µM 0.6 µM 
Taq Polimerase 5U/µl 0.04 U/µl 
DNA 60 ng/ µl 5ng/ µl 
H2O q.b q.b 
 
Table 1: amplification conditions for PCR 
 
 
 
 
Temperature Time Cycle 
94° C 2 min. 1 
94° C 20 sec.  
 
 
14 TA°C + 7°C   40 sec. ↓ 0.5°C/cycle 
65°C 45 sec. 
94° C 20 sec.  
 
 
25 TA°C 40 sec. 
65°C 45 sec. 
65°C 7 min. 1 
 
Table 2: amplification program for PCR 
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TA  is the annealing temperature of primers, calculated according 
to the following formula: 
TA = {[(A+T)•2+(G+C)•4]-5}°C 
A+T = Adenosine + Timidine 
G+C = Guanidine + Citidine 
 
 
3.5 Primer design 
PCR primers were designed to generate amplicons to 
cover the coding regions and exon-flanking intronic 
sequences of the PAH gene. Specific primers were 
generated using the web-based program Primer3 
(http://frodo.wi.mit.edu/primer3/) (v.0.4). The criteria for 
primers were: 20 base pairs in length; melting temperature 
(Tm) of 57-60 °C; and G/C content 45-60%. Primers were 
also checked by BLASTn against the NCBI genome data 
bank for specificity 
(http://www.ncbi.nlm.nich.gov/tools/primer-blast/)   and 
were tested for loop formation by using the DINA Melt web 
server (http://mfold.rna.albani.edu/?q=DINAMelt/Two- 
state-folding). The primer sequences are reported in Table 
3. 
 
 
 
 
 
EXONS FORWARD REVERSE 
1 5’TACCTGAGGCCCTAAAAAGC3’ 5’CTTCGGATCTCTTTCTCTGGA3’ 
2 5’ATGCTTGCTTTGTCCATGG3’ 5’CAAATCTGCCTGTTCCAGATC3’ 
3 5’GGACGTTGCCTTCTCTGTGT3’’ 5’TGTTGCAAAATTCCTCTAATTCTT3’ 
4 5’GTTATCTGGAAGCCAGCCC3’ 5’GCCCTCGTGTAAATAGGAACA3’ 
5 5’ACCAGGCCTCTTCCTATGAA3’ 5’TCTTCCCCTCAACAAGCAA3’ 
6 5’GCCCTGCTTGAGACACCTAT3’ 5’CATTGACCCTGATGTGGACTT3’ 
7 5’CTCAGTGGTGATGAGCTTTGA3’ 5’TCATTCTTGCAGCAGGAAAA3’ 
8 5’TCTGGCTTGGCTTAAACCTC3’ 5’CTCCCTGGGCTCAACTCAT3’ 
9 5’GGTTGGTTCTGTGGTTCCA3’ 5’CCTATAGCACTCCACCATCCA3’ 
10 5’TCCCTTCATCCAGTCAAGGT3’ 5’CTGGAGAATGAGTTCCCAGG3’ 
11 5’GCAGCAGGGAATACTGATCC3’ 5’CCAGAGCTAGTGGCTCACCT3’ 
12 5’TTCTCCAAATGGTGCCCTT3’ 5’TGAGAAACCGAGTGGCCTC3’ 
13 5’TGCTTTGCACTGAGGACACT3’ 5’TGCTTTTCGGACTTTTTCTGA3’ 
 
Table 3: Primer sequences for the amplification of the 13 
exons of PAH gene. 
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3.6 Direct sequencing 
The direct sequencing was performed using the protocol of 
Sanger;  the  fragments  obtained  were  subsequently 
analyzed on both strands with an automated procedure 
using the 3100 Genetic Analyzer (Applied Biosystem). All 
PCR fragments were sequenced using the same primers 
used for PCR amplification. The results are represented by 
electropherograms (Fig. 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13: Example of electropherogram obtained by Genetic 
Analyzer. 
 
 
 
3.7 Next Generation Sequencing 
To perform the comprehensive sequence analysis of the 
entire PAH gene by a NGS approach, we used a Long-PCR 
strategy  to  enrich  our  target  gene.  Totally,  we  analyzed 
106.270 bp, including 22.000 bp at the 5’ end of the 
transcription start site and 1000 bp at the 3’ end of the coding 
gene. The genomic coordinates of PAH gene were derived 
from the website “http://genome.ucsc.edu/” (NM 000277.1, 
Human  Genome  assembly  GRCh37/hg19,  Feb.2009, 
genome coordinates Chr 12: 103,227,104-103,333,381). 
Sixteen overlapping Long-PCR amplicons, ranging in size 
between 3-12 kb, were generated in order to cover the 
promoter and all the coding and non-coding regions of PAH 
gene.   Specific   primers   were   generated   using   Primer3 
software “http://frodo.wi.mit.edu/primer3/”. To design an 
efficient and gene-specific primer set, known SNPs and 
regions of the gene that contain repeated sequences were 
masked. Primers inclusion criteria were: 20 base pairs in 
length; melting temperature (Tm) of 57–60 °C; G/C content of 
45–60%. Primers were also checked by BLASTn against the 
44 
 
NCBI genome data bank for  specificity 
(http://www.ncbi.nlm.nich.gov/tools/primer-blast/) and were 
tested for loop formation by using the DINAMelt web server 
(http://mfold.rna.albani.edu/?q=DINAMelt/Two-state-folding). 
Consecutive primer sets were designed to overlap at least 
150-600 base pairs to ensure good coverage and continuity 
at the ends of amplicon sequences. The amplification 
conditions of each amplicon were optimized using control 
DNAs. Primer testing was performed using 60-120 ng of 
human genomic DNA in a PCR core mix containing 200 nM 
of each forward and reverse primers, 250 mM each dNTP, 
50 ng/ml BSA, 1X PFU Ultra II Reaction Buffer (Agilent 
Technologies. Inc.) and two units of PfuUltra II Fusion HS 
DNA Polymerase (Agilent Technologies. Inc.). PCR primers 
and amplicon lengths are listed in Table 4. Thermal cycling 
reactions were performed on a DNA Engine ® (Bio-Rad 
Laboratories, Hercules, CA) using the following “touch down” 
cycling profile: one cycle at 92°C for 2 min (initial 
denaturation), followed by five cycles at 92°C for 10 s 
(denaturation), at 62°C for 20 s (annealing; -1°C every cycle) 
at 68°C for 4 min (extension), followed by 25 cycles at 92°C 
for 10 s (denaturation), at 58°C for 20 s (annealing), at 68°C 
for 4 min (extension), followed by a final extension step at 
68°C for 5 min. The above mentioned PCR amplification 
conditions were used for the following amplicons: PKU1, 
PKU2, PKU3, PKU4a and the ones at the 3’ end PKU 10 and 
PKU 11 (see Table 4). 
For amplicons that failed to be amplified, we attempted three 
additional modified thermal cycling conditions. The first profile 
reduced the annealing temperature for the first cycle after the 
initial denaturation to 65°C with a further -1°C reduction of the 
annealing temperature every cycle for the next 4 cycles. The 
second profile reduced the annealing temperature for the first 
cycle after the initial denaturation to 60°C with a further -1°C 
reduction of the annealing temperature every cycle for the next 
4 cycles. The third profile, regarding 6b and 9a exons (see 
Table 4), increased the extension times of the last 25 cycles 
by 8 seconds every cycle. Any primer pair that failed to amplify 
with all four PCR profiles was discarded and new primers were 
designed. All the PCR products were visualized on 0.7% 
agarose gel. 
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Amplicon 
 
Region 
size (bp) 
 
Primer 
 
Primer sequences 
 
PKU1 
 
11706 
1F 
 
5’-GGGCTGTCAGTGGAAATGTT-3’ 
1R 5’-TGGTGCCTGATGCACATTAT-3’ 
 
PKU2 
 
11644 2F 5’-CTTCTGCCTGGAAGGTTCTG-3’  
2R 5’-TATTCGCACAACTGCTCCTG-3’ 
 
PKU3 
 
9975 3F 5’-TGCCTCACCCTCAGTCTTCT-3’  
3R 5’-TCTTGAGTGCATTCCATCCA-3’ 
 
PKU4a 
 
11724 4aF 5’-GTTCATGCTTGCTTTGTCCA-3’  
4aR 5’-GTGGGCTATCTGGGTTCAAA-3’ 
 
PKU4b 
 
4545 4bF 5’-CCCTCCCAGAAGAGGAAATC-3’  
4bR 5’-ACTGAACCCCCAACACAAAG-3’ 
 
PKU5a 
 
4620 5aF 5’-CCTCCCTTCCAAAACTCTCC-3’  
5aR 5’-TGCTGTTATTTTATGAAGACAGTGTG-3’ 
 
PKU5b 
 
5719 
5bF 5’-TCTCCATTTTGTTGCGTTAGG-3’ 
5bR 5’-GAAGAAACTCAAGAAGGCAAGG-3’ 
 
PKU6a 
 
6983 6aF 5’-CGAGTCTGACAGCAGGTTCA-3’  
6aR 5’-AATGCACAGCCTCATTTTCC-3’ 
 
PKU6b 
 
6158 6bF 5’-AGGTGGCCCGATAAGAATTT-3’  
6bR 5’-TCCCAGCCCTCGTGTAAATA-3’ 
 
PKU7 
 
5119 7bF 5’-GATCCCCACTTCTGATCTCA-3’  
7bR 5’-GAACTCTGACAGGGCCTCAG-3’ 
 
PKU8a 
 
3428 8aF 5’-TTCACTTCCAATGTGGGTCA-3’  
8aR 5’-AGGGGATAGAAGACGGGAGA-3’ 
 
PKU8b 
 
7708 8bF 5’-TGGTTTAAAAGCCCCTTGTG-3’  
8bR 5’-CTTGTGGTAGCCAGCAATGA-3’ 
 
PKU9a 
 
8092 9aF 5’-CTTGGGCAAGAGCTTACCTG-3’  
9aR 5’-CCCCCATGTTCTCTGTGTCT-3’ 
 
PKU9b 
 
3759 9bF 5’-GCCCTGCTTGAGACACCTAT-3’  
9bR 5’-CTCCCTGGGCTCAACTCAT-3’ 
 
PKU10 
 
9792 10F 5’-CTTAAGACCCTTGGCTGCTG-3’  
10R 5’-CTGCCTCTAAGCTCCAATGC-3’ 
 
PKU11 
 
8762 11F 5’-TCTGAGACTGTTGGCCCTCT-3’  
11R 5’-CAACAAATGTGGGTGCTGTC-3’ 
 
Table 4: Primer sequences and amplicon lengths of the 16 
overlapping regions PAH gene to be sequenced by NGS. 
 
 
Each amplicon was individually amplified and purified using an 
equal volume of AMPure Reagent beads (Agencourt, Beverly, 
MA)    according    to    the    manufacturer’s    protocol.    After 
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appropriate  quality  assessment  (DNA  7500  LabChip,  2100 
BioAnalyzer, Agilent) and quantification (Picogreen assay, 
Invitrogen), the amplification products from the same DNA 
sample were pooled in equimolar ratio. Each amplicon pool 
was used to generate a library to be processed using the GS 
FLX System (454 Life Science and Roche) by shotgun 
approach, according to the specifications of the manufacturer. 
Briefly, 5 µg of amplified and pooled DNA from each patient 
were nebulized into small fragments, purified and assessed for 
quality. Blunt-ends were generated and specific adaptors with 
Multiplex Identifiers (MID) were ligated to the ends of each 
fragment.  MID  adaptors  include  a  sequence  tag  which  is 
unique for each MID and allow the simultaneous sequence of 
different patients. So, we generated a single stranded library 
with a specific MID for each sample. Then, different libraries 
were pooled together, immobilized on the surface of 
microscopic beads and clonally amplified within the droplets of 
a water-in-oil emulsion. Amplification of the entire fragments 
collection was done in parallel, resulting for each fragment in a 
copy  number  of  several  million  per  bead.  The  clonally 
amplified fragments were enriched, loaded into wells of a fibre- 
optic slide (PTP), and bi-directionally sequenced using a 
pyrosequencing protocol (33 b). 
 
 
 
3.8 Bioinformatic Analysis 
All the obtained sequencing reads were quality filtered and 
trimmed by the data analysis software, so that sequencing 
adaptors were removed and the reads from each of the pooled 
libraries  were  identified  by  their  MID  tag  and  correctly 
assigned to each analyzed sample. Next, the filtered reads 
were mapped against the human genome reference sequence 
to generate a list of variants for further investigations. 
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4. Results 
4.1 Molecular diagnosis of PAH mutations 
We have analyzed 390 PKU patients and 373 carriers. 
Patients are mainly from the centre of Screening 
Annunziata Hospital of Naples and, based on the L-Phe 
concentrations found in the blood, were divided into three 
groups: 121 were classified as (15.8%) PKU, 64 (8.4%) as 
HPAII and 205 (26.9 %) as HPAIII. 
 
 
Fig. 14: Graphical representation of studied population. 
We analyzed both patients and carriers. 
 
 
 
Molecular analysis identified mutations in 763/780 alleles 
with an allele detection rate of 97.8%. Complete 
sequencing of the 13 exons, the intron–exon boundaries 
and the promoter region of the PAH gene was carried out. 
Complete genotyping was carried out in 763/780 alleles. 
In seventeen patients only one causative mutation was 
found. 
The failure to identify a mutation in one of the 2 alleles 
may be due to: 
1) Alterations present in the promoter region or in the 
region of the 3' untranslated 
2) Molecular defects that affect introns 
3) Mutations of an enhancer 
4) Large deletions or duplications of the PAH gene 
A total of 105 distinct mutations were identified and these 
were not uniformly distributed along the PAH gene 
sequence (Table 4). 
Of the 105 variants, 76 were missense mutations (74%), 
20 alter splicing site (18%), 5 were deletions (4%) and 4 
were  frame-shift  (4%).  The  data  obtained  are  in 
agreement  with  those  reported  in  the  literature  and 
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confirm the highest frequency of the missense mutations 
in PKU (60.68%). 
 
 
 
Fig.  15:  Graphical  representation  of  mutations  of  PAH 
gene in PKU patients 
 
 
 
 
4.2 Prenatal Diagnosis 
We performed prenatal diagnosis in three families at high 
risk for HPA: 
1. The prenatal diagnosis has been requested for a foetus 
in a family with an affected baby. Therefore, we performed 
the molecular analysis of the PAH gene of the affected 
son, of the parents and finally of the baby. The molecular 
analysis of the affected son revealed the genotype 
R261Q/P281L. Molecular analysis performed on DNA 
extracted from peripheral blood of the parents showed the 
presence of the R261Q mutation for the father and 
mutation P281L for the mother in the heterozygous state, 
so  the  genotype  is  compatible  with  the  healthy  carrier 
state. Finally, the molecular diagnosis performed on DNA 
extracted from amniocytes has demonstrated the absence 
of both mutations R261Q and P281L, previously identified 
in the parents, providing a healthy phenotype for 
phenylketonuria. 
2. The prenatal diagnosis has been requested for a foetus 
with an affected brother. Molecular analysis performed on 
DNA extracted from peripheral blood of the parents 
demonstrated the presence of the mutation in the 
heterozygous p.P281L in the mother and p.A403V in the 
father, so the genotypes are compatible with the carrier 
state. The molecular diagnosis performed on DNA 
extracted  from  chorionic  villi  showed  the  presence  of 
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mutations p.A403V and p.P281L both in the heterozygous 
allowing, therefore, to provide a genotype 
p.A403V/p.P281L compatible with a phenotype affected 
by hyperphenylalaninemia. 
3. The prenatal diagnosis has been requested for a foetus 
by an affected mother. Molecular analysis performed on 
DNA extracted from peripheral blood of the mother 
demonstrated  the  presence  of  the  mutations  p.W187C 
and p.R261Q, both heterozygous, so the genotype is 
p.W187C/p.R261Q, and this genotype is compatible with 
the  state  of  suffering  from  phenylketonuria.  On  the 
contrary, the molecular analysis performed on DNA 
extracted from peripheral blood of the father showed no 
causal mutations of disease. It should be emphasized, 
however, that the analysis of sequencing used includes 
the regions comprising the 13 exons and exon junctions- 
intron of the PAH gene, therefore, it is not possible to 
exclude mutations present in other regions of the PAH 
gene, not identifiable with current techniques in use. The 
molecular diagnosis performed on DNA extracted from 
amniocytes showed the presence of the mutation in 
heterozygous p.R261Q and the absence of the mutation 
p.W187C, allowing, therefore, to predict a phenotype of 
bearer not suffering from phenylketonuria.In this case, we 
suggested to family to control the Phe mother during the 
pregnancy through a Phe restricted diet in order to prevent 
damages from Maternal PKU. 
 
 
 
4.3 Molecular epidemiology of PAH mutations 
The  mutations  identified  in  the  390  patients  and  their 
frequencies are shown in Table 5 which shows the data 
for the 780 alleles studied (column 7), and those related to 
three classes of PKU patients. 
The frequencies of the mutations p.R261Q, p.A403V and 
c.1066-11G> A were higher than 10%, (cumulative 
frequency= 24.8%); the mutations p.L48S and p.A300S 
had a frequency in the range of 6-10%, (cumulative 
frequency = 13.6%); 51 mutations in the range of 0.2%- 
3.2% (cumulative frequency = 56.9%); 47 mutations have 
been found in a single mutant allele with a frequency of 
0.1%(cumulative frequency = 4.7%). In 17 patients (4.3%) 
only one mutation was identified. The major part of the 
mutations (n=81) was located along the catalytic domain 
(78%), 18 mutations were found in the regulatory domain 
(17.3%) and 5 belonged to the tetrameric domain (4.8%). 
The mutation p.R261Q, in the exon 7 is the most common 
mutation in our population (13.4%) being present in 89 of 
these, 35 patients with PKU phenotype (27 heterozygous 
and 8 homozygous), in 21 patients with HPAII phenotype 
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(14 heterozygous and 7 homozygous) and in 33 patients 
with HPAIII phenotype (32 heterozygous and 1 
homozygous). The R261Q mutation is due to a transition 
G>A, in position 782 to the nucleotide sequence, which 
corresponds to an amino acid substitution (Arg>Gln), 
resulting in a lack of interaction of the catalytic site with 
the cofactor BH4 (45). 
The second most frequent mutation in Campania is the 
p.A403V (11.4%) in exon 12. The mutation is present in 
76 subjects with HPAIII phenotype (71 heterozygotes and 
5 homozygotes) (18.5%), in 7 patients with HPAII (5.4%) 
and in 1 patient with PKU (0.4%); therefore this mutation 
appears to be strongly related to the mild phenotype. 
p.A403V mutation is characterized by an amino acid 
substitution (Ala>Val) caused by a transition C>T in 
position 1222. The mutation is not directly involved in 
alterations of the catalytic activity, in fact falls within the 
group of mutations that alter the mechanism of binding of 
the cofactor; in fact, the exon 12 encodes for some 
elements of the secondary structure of PAH necessary for 
the interaction with the BH4 and the mutations determine 
the production of proteins with decreased affinity for the 
cofactor (45). 
The mutation c.1066-11G> A is the third most frequent 
mutation (11.1%) and appears to be more closely related 
to the phenotype PKU. In fact, it was found in 44 PKU 
patients (18.1%) (33 heterozygous and 11 homozygous), 
in  15  patients  with  HPAII  (11.7%)  and  in  17  HPAIII 
patients (4.1%). The mutation, which falls in exon 10, 
causes a splicing site alteration with the insertion of 9 
nucleotides between exon 10 and exon 11 leading to the 
production of a protein with 3 additional amino acids (Gly- 
Leu-Gln). The insertion of these 3 amino acids probably 
alters the structure of the protein, which forms protein 
aggregates and loses its functionality (46). 
Another very frequent mutation in Campania is the p.L48S 
(7.6%). This mutation was reported in 21 PKU patients 
(8.7%), in 11 HPAII patients (8.6%) and in 21 HPAIII 
patients (5.1%) (18 heterozygotes and 3 homozygotes), 
so  it  is  mainly  related  to  PKU  phenotype  and  HPAII. 
p.L48S falling in exon 2 is probably involved in alterated 
mechanism of auto-regulation of the enzyme. p.L48S is a 
mutation that replaces the amino acid Leu in Ser; it is due 
to a transition T>C in position 143 of the nucleotide 
sequence. Finally the last most frequent mutation detected 
in Campania is the A300S (6%). A300S is due to a G>T at 
position  898  of  the  nucleotide  sequence  of  the  gene, 
which causes an amino acid substitution (Ala>Ser) and 
directly  alters  the  binding  site  of  the  enzyme  for  its 
cofactor thus determining a reduced affinity for BH4 (42). 
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It was reported that mutations in exon 8 are related to 
changes in the catalytic activity as well as to a decrease 
interaction PAH-BH4. 
 
 
 
 
 
Exon 
 
Protein Domain and 
Subdomain 
 
 
Mutation 
 
PKU 
(242) 
 
HPAII 
(128) 
 
HPAIII 
(410) 
 
Total 
(780) 
 
1  
 
 
 
 
Regulatory Domain 
nt 1-426 
aa 1-142 
 
 
 
 
 
Auto Regulatory 
Domain 
 
nt 55-99 
aa 19-33 
 
c.47-48delCT 
 
0,4 
 
0,7 
 
0,2 
 
0,4 
 
 
 
 
 
2 
 
p.F39del 
 
0 
 
0 
 
0,5 
 
0,2 
 
p.L48S 
 
8,6 
 
10,9 
 
5,6 
 
7,6 
 
p.F55L 
 
0 
 
0 
 
0,5 
 
0,2 
 
c.168+1G>A 
 
0 
 
1,56 
 
0 
 
0,2 
 
c.168+5G>C 
 
0,4 
 
0 
 
0,2 
 
0,2 
 
p.R53H 
 
0 
 
0 
 
0,2 
 
0,1 
 
p.F55>Lfs 
 
5 
 
0,8 
 
1,2 
 
2,3 
 
 
 
 
 
 
 
3 
 
p.T921 
 
0 
 
0,8 
 
0,2 
 
0,2 
 
p.E76X 
 
0,4 
 
0 
 
0,2 
 
0,2 
 
p.I95_K96delinsK 
 
0 
 
0 
 
0,2 
 
0,1 
p.l95T 
 
0 
 
0 
 
0,2 
 
0,1 
 
p.l95del 
 
0,4 
 
0 
 
1,5 
 
0,9 
 
p.L62X 
 
0 
 
0 
 
0,2 
 
0,1 
 
p.S67P 
 
1,2 
 
0 
 
0,5 
 
0,6 
 
p.l65T 
 
0 
 
0,8 
 
0 
 
0,1 
p.I65M 
 
0 
 
0 
 
0,2 
 
0,1 
 
p.l94S 
 
0 
 
0 
 
0,5 
 
0,2 
 
 
 
4 
 
c.441+5G>T 
 
2 
 
0,8 
 
1,2 
 
1,4 
 
 
Catalytic Domain 
nt 427-1230 
aa 143-410 
 
 
 
Cofactor Binding 
Region # 1 
nt 733-798 
aa 245-266 
 
 
 
Cofactor Binding 
Region # 2 
nt-838-849 
aa 280-283 
 
 
 
Cofactor Binding 
Region # 3 
nt 964-978 
aa 322-326 
p.N133_Q134>Rfs 0,4 0 0 0,1 
 
c.441+1G>A 
 
0,4 
 
0 
 
0,7 
 
0,5 
 
p.D145V 
 
0 
 
0 
 
0,2 
 
0,1 
 
p.Q134X 
 
0,4 
 
0 
 
0,2 
 
0,2 
 
 
 
 
 
5 
 
p.R158Q 
 
4 
 
3 
 
1,2 
 
2,4 
 
p.R158W 
 
0,4 
 
1,6 
 
0 
 
0,4 
 
p.R155H 
 
0 
 
0 
 
0,2 
 
0,1 
 
p.R169H 
 
0 
 
0 
 
0,2 
 
0,1 
 
c.442-5C>G 
 
0 
 
1,6 
 
2 
 
1,3 
 
c.442-2A>C 
 
0,4 
 
0,8 
 
0,2 
 
0,4 
 
p.G148S 
 
0 
 
0,8 
 
0 
 
0,1 
 
 
 
 
 
 
6 
 
p.D222G 
 
0,8 
 
0 
 
1,4 
 
1 
p.N223Y 
 
0 
 
0 
 
0,5 
 
0,2 
 
p.S231P 
 
1,2 
 
0,8 
 
1,5 
 
1,3 
 
p.N207S 
 
0 
 
0,8 
 
0 
 
0,1 
 
p.E178G 
 
0 
 
0,8 
 
1 
 
0,6 
 
p.R176L 
 
0 
 
0 
 
0,1 
 
0,1 
 
p.R176X 
 
0,8 
 
0,8 
 
0,8 
 
0,7 
 
p.V230l 
 
0 
 
0,8 
 
1,5 
 
0,8 
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p.G218V 0 0 0,2 0,1 
 
p.V177M 
 
0 
 
0 
 
0,8 
 
0,4 
 
p.W187C 
 
0,4 
 
0 
 
0 
 
0,1 
 
p.Q232Q 
 
0,4 
 
0 
 
0 
 
0,1 
 
p.W187X 
 
0,8 
 
0,8 
 
0,8 
 
0,8 
p.Q235X 
 
0,4 
 
0 
 
0 
 
0,1 
 
p.P211T 
 
0 
 
0 
 
0,2 
 
0,1 
 
p.L213P 
 
0,8 
 
0 
 
0,8 
 
0,6 
 
p.V177L 
 
0 
 
0 
 
0,2 
 
0,1 
 
c.592-613del22 
 
0,8 
 
0 
 
0 
 
0,2 
 
p.R261Q 
 
17.07 
 
22 
 
8,3 
 
13,4 
 
p.R261X 
 
2,4 
 
1,5 
 
0 
 
1 
 
c.842+3G>C 
 
1,2  
 
1,2 
 
1 
 
p.R252Q 
 
0 
 
0,8 
 
0,2 
 
0,2 
 
p.R243Q 
 
0 
 
0 
 
0,2 
 
0,1 
 
p.P275L 
 
0 
 
0,8 
 
0 
 
0,1 
 
c.842+1G>A 
 
0,4 
 
0 
 
0 
 
0,1 
 
p.281L 
 
5,8 
 
6,2 
 
0,8 
 
3,2 
 
p.L242F 
 
0 
 
0,8 
 
0 
 
0,1 
 
p.G272X 
 
0,8 
 
0 
 
0 
 
0,2 
 
p.243Q 
 
0,4 
 
0 
 
0 
 
0,1 
 
p.R241C 
 
0 
 
0 
 
0,5 
 
0,2 
 
p.E280K 
 
0,8 
 
0 
 
0,2 
 
0,4 
 
p.R252W 
 
1,6 
 
0 
 
0,8 
 
0,9 
 
p.R243X 
 
0,4 
 
0 
 
0,5 
 
0,4 
 
p.R241H 
 
0 
 
0 
 
0,2 
 
0,1 
 
p.V245A 
 
0 
 
0,8 
 
1,2 
 
0,8 
 
c.707-2delA 
 
0,4 
 
0 
 
0 
 
0,1 
 
p.A300S 
 
0 
 
4,6 
 
9,7 
 
6 
 
p.l283N 
 
0 
 
0 
 
0,2 
 
0,1 
p.R297L 
 
0 
 
0 
 
0,2 
 
0,1 
p.Q301P 
 
0,4 
 
0 
 
0 
 
0,1 
 
p.S303A 
 
0 
 
0 
 
0,2 
 
0,1 
 
c.969+43G>T 
 
0 
 
0 
 
0,5 
 
0,2 
p.L321l 
 
0 
 
0 
 
0,2 
 
0,1 
 
p.A309V 
 
0 
 
0,8 
 
0 
 
0,1 
 
c.913-7A>G 
 
0 
 
0 
 
0,2 
 
0,1 
 
p.l306V 
 
0 
 
0 
 
0,2 
 
0,1 
 
p.W326S 
 
0 
 
0,8 
 
0 
 
0,1 
 
c.1055delG 
 
1,6 
 
0 
 
0 
 
0,5 
 
p.G352fs 
 
2,9 
 
0 
 
0,8 
 
1,3 
 
p.D338Y 
 
0 
 
2,3 
 
1,2 
 
1 
 
c.1066-11G>A 
 
22,7 
 
11.07 
 
4 
 
11,10 
 
p.K363fs 
 
0,4 
 
0 
 
0 
 
0,1 
 
p.A395G 
 
0 
 
0 
 
0,2 
 
0,1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
 
 
8 
 
 
 
9 
 
 
 
10 
 
 
11 
 
 
 
 
 
Cofactor Binding 
Region # 4 
 
nt 1129-1137 
aa 377-379 
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p.E390G 0 2,3 2 1,4 
 
p.P366H 
 
0,8 
 
0 
 
3,6 
 
2,2 
p.F382L 0 0 0,2 0,1 
 
p.V388M 
 
0 
 
0 
 
0,5 
 
0,2 
 
p.T380M 
 
0 
 
0 
 
2 
 
1 
 
c.1066nt4A>C 
 
0 
 
0 
 
0,2 
 
0,1 
 
p.Y387H 
 
0 
 
0 
 
0,2 
 
0,1 
 
c.1199nt4A>C 
 
0 
 
0 
 
0,2 
 
0,1 
 
c.1066-3C>T 
 
0 
 
0,8 
 
0 
 
0,1 
 
p.K398N 
 
0 
 
0 
 
0,2 
 
0,1 
 
c.1315nt2T>C 
 
0 
 
0,8 
 
0 
 
0,1 
 
c.1315+1G>A 
 
0,8 
 
1,5 
 
0,2 
 
0,6 
p.A403V 0,4 5,4 20 11,4 
p.Y414C 0 1,5 1,5 1 
p.N426H 0 0 0,2 0,1 
p.R408Q 0 0 0,5 0,2 
 
p.R408W 
 
3 
 
0,8 
 
1,2 
 
1,6 
p.I406M 0 0 0,2 0,1 
p.Q419R 0 0 0,2 0,1 
p.T418l 0 0 0,5 0,2 
  
0 
 
0 
 
0 
 
0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 
Tetramerizazion 
Domain 
nt 1231-1356 
aa 411-452 
 
 
13 
 
 
Table 5: Alleles and relative frequencies of 103 mutations 
in PAH gene in 780 alleles of HPAs patients in Campania. 
Novel mutations are highlighted in red; 
 
 
 
Flow chart definition 
Based on the epidemiologic data and according to 
phenotype of patients, we created a comprehensive flow 
chart for the detection of nucleotide alterations (Fig. 16). 
This flow chart represents a simple, elegant and less 
expensive step-by-step procedure for reliable detection of 
PAH mutations. The method is simple to perform and easy 
to implement in a routine diagnostic laboratory. Based on 
the biochemical phenotype of the patient who arrives at 
our lab, we firstly proceed to the amplification and 
sequencing  of  exons  more  implicated  (with  high 
frequency) in that class of patients. Successively, if the 
mutations responsible for the disease are not identified, 
we proceed to the analysis of exons gradually less 
frequently mutated in the specific phenotype. This method 
can  reduce  both  costs  and  analysis  time  of  patients 
starting from their biochemical phenotype. 
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Fig. 16: Analytic flow chart for the molecular analysis of 
the PAH gene in Campania patients affected by PKU. 
 
The mutations found in patients fall throughout the entire 
PAH  gene  without  a  real  mutational  hot  spot,  each 
causing different effects on the activity of PAH enzyme. In 
Table   6   are   reported   the   mutations   found   in   our 
population, each with the relative frequencies as well as 
the exon in which are present. As shown in Table 5 the 
exon 7 is the region in which the majority of mutations fall; 
it contains about the 23.8% of the total mutations, the 
percentage arises to 33.7% considering only the PKU 
patients. Moreover, the PAH gene corresponding to the 
exon 11 together with the exon 12 contains about 34.4 % 
of total mutations (the percentage arises to 39% 
considering only the HPAIII patients and 28% considering 
PKU). Exon 2 contains 11.5% of total mutations. The 
remaining exons (1, 3, 4, 5, 6, 8, 9 and 10) contain 
between 0.4 and 8.3% of total mutations. In exon 1 has 
been identified a single mutation and in exons 9 and 10, 
five and four respectively. No mutation has been identified 
in exon 13. 
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The frequencies of mutations per exons are represented 
in Fig. 17. Panels A, B, C, D show mutation frequency in 
PKU, HPAII, HPAIII and total patients respectively. 
 
 
 
 
 
 
 
Exon 
Protein Domain and 
Subdomain 
 
PKU 
 
HPAII 
 
HPAIII 
 
Total 
 
1 
 
 
 
 
Regulatory Domain 
nt 1-426 
aa 1-142 
 
 
 
 
 
 
 
Auto Regulatory Domain 
nt 55-99 
aa 19-33 
0.4% 0.7% 0.2% 0.4% 
 
 
 
 
 
2 
 
 
 
 
 
14.9% 
 
 
 
 
 
13.4% 
 
 
 
 
 
8.9% 
 
 
 
 
 
11.5% 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
2.19% 
 
 
 
 
 
 
 
1.6% 
 
 
 
 
 
 
 
4.10% 
 
 
 
 
 
 
 
3% 
 
 
 
4 
 
 
 
3% 
 
 
 
0.7% 
 
 
 
2.5% 
 
 
 
2.5% 
Catalytic Domain 
nt 427-1230 
aa 143-410 
 
 
 
 
 
 
 
Cofactor Binding Region #1 
nt 733-798 
aa 245-266 
 
 
 
 
Cofactor Binding Region #2 
nt 838-849 
aa 280-283 
 
 
 
Cofactor Binding Region #3 
nt 964-978 
 
 
 
 
 
5 
 
 
 
 
 
5.26% 
 
 
 
 
 
7.9% 
 
 
 
 
 
4.10% 
 
 
 
 
 
5% 
 
 
 
 
 
 
6 
 
 
 
 
 
 
7% 
 
 
 
 
 
 
4.8% 
 
 
 
 
 
 
10% 
 
 
 
 
 
 
8.32% 
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7 
 
 
 
8 
 
 
 
9 
 
 
 
10 
 
 
 
11 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
33.7% 
 
 
 
 
 
 
 
 
 
 
 
 
 
34.1% 
 
 
 
 
 
 
 
 
 
 
 
 
 
14.8% 
 
 
 
 
 
 
 
 
 
 
 
 
 
23.8% 
 
 
 
0.4% 
 
 
 
5% 
 
 
 
11% 
 
 
 
6.71% 
 
 
 
0% 
 
 
 
0.7% 
 
 
 
1.3% 
 
 
 
0.8% 
 
 
 
4.8% 
 
 
 
3% 
 
 
 
2% 
 
 
 
3% 
 
 
 
23.6% 
 
 
 
17.4% 
 
 
 
15% 
 
 
 
18% 
 
aa 322-326 
 
 
 
 
 
Cofactor Binding Region #4 
nt 1129-1137 
aa 377-379 
57 
 
    
 
 
 
 
 
 
4.4% 
 
 
 
 
 
 
10.3% 
 
 
 
 
 
 
25.3% 
 
 
 
 
 
 
16.3% 
 
0% 
 
0% 
 
0% 
 
0% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 
 
Tetramerizazion Domain 
nt 1231-1356 
aa 411-452 
 
 
13 
 
 
Table  6:  Distribution  of  the  mutations  along  the  PAH 
Fig. 17: Graphical  representation 
in total PKU patients.
PKU,   HPAII,   HPAIII  
  
 
 of mutation  frequencies per exon
 Panels A, B, C, D show mutation   frequency
 and   total patients respectively. 
  
 in 
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4.4 Genotype-phenotype correlation 
We studied correlation between genotype and phenotype. 
The genotype correlates well with phenotype in about 75% 
of total patients. These results are in accord with the 79% 
correlation rate previously reported (14). 59 patients (15%) 
have a homozygous genotype: 31 PKU phenotype 
corresponding  to  52.5%; 9  HPAII phenotype 
corresponding to 15.3%; 19 HPAIII phenotype 
corresponding to 32.2% (Table 7); among them, we found 
that: the R261Q mutation was present in 16 patients, 8 
PKU, 7 HPAII and 1 HPAIII according to the value of 
residual in vitro enzymatic activity; c.1066-11G>A was 
present  in  11  PKU  patients;  and  L48S  present  in  5 
patients,  in  this  case,  the  L48S  homozygosity is 
associated  with  different  phenotypic  classes,  i.e.  HPAII 
and HPAIII. In addition, 5 HPAIII patients are homozygous 
for the mutation A403V according to the residual in vitro 
enzymatic activity; 4 PKU patients are homozygous for the 
mutation p.F55>Lfs  and  4  HPAIII  patients  are 
homozygous for P366H. 3 PKU patients are each 
homozygous for the mutations p.G272X, p.P281L and 
p.R261X, respectively. From the analysis of the genotype- 
phenotype  data,  it  results  that  p.R261Q  and  c.1066- 
11G>A mutations are mainly associated with severe PKU 
phenotype while p.A403V mutation is strongly associated 
to   a   mild   phenotype   while,   in   contrast,   p.L48S   is 
associated with HPA II and HPAIII phenotypes. 
In addition, considering the PKU heterozygous patients, 
the most frequent mutation is the c.1066-11G>A (21%) 
followed by p.R261Q (17.3%), p.L48S (8.6%), p.281L 
(5.8%), p.F55>Lfs (5%). In HPAII patients, the most 
common mutations are p.R261Q (23%), c.1066-11G>A 
(13.2%), p.L48S (10.9%), p.281L (6.2%) and p.A403V (6.2 
%); finally, in HPAIII patients, the most common mutations 
are p.A403V (20%), p.A300S (9.7%), p.R261Q (8.3%), 
p.L48S (5.6%) and c.1066-11G>A (5%). From the analysis 
of these data, we may conclude that c.1066-11G> A and 
p.R261Q mutations are more related to severe phenotype 
(PKU and HPAII); p.A403V p.A300S mutations are more 
related to mild HPAIII phenotype. Therefore, it can be 
concluded in 75% of analyzed patients, there is a good 
correlation genotype-phenotype. 
Furthermore, there are some patients (about 5%) that, 
although presenting the same genotype, manifest different 
phenotypes; for example patients with genotype 
p.L48S/p.R261Q have a severe PKU or mild HPAIII 
phenotypes. Then, for few patients there is a discrepancy 
between genotype and phenotype. In conclusion, the 
metabolic  phenotype  of  the  analyzed  patients  is  not 
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completely  in  accord  to  that  expected,  conclusion  not 
feasibly justifiable for a monogenic disease such as PKU. 
Several reasons can be attributed to this discrepancy: 
 Phenotypic classifications incorrect; 
 Combination of different subunits encoded by 
mutant alleles in the homotetramer protein 
 The action of modifier genes 
Note that we must take into account that the classification 
on the basis of tolerance to L-Phe depends on both the 
maximum concentration of L-Phe that can be administered 
according to the age of the patient since it is known that 
the concentration of L-Phe varies with growth. 
With regards to the combination of different monomers to 
form tetramers, there are 16 different combinations and 
the result of this interaction is not always predictable. 
Finally  the  phenotypic  variability  that  concerns  patients 
with  the  same  genotype  may  depend  on  differences 
between individuals regarding the presence of molecular 
chaperons aiming to stabilize the mutant protein. 
 
 
 
Mutation PKU HPAII HPAIII Total 
 
p.R261Q 
 
8 
 
7 
 
1 
 
16 
 
c.1066-11G>A 
 
11 
 
0 
 
0 
 
11 
 
p.L48S 
 
0 
 
2 
 
3 
 
5 
 
p.A403V 
 
0 
 
0 
 
5 
 
5 
 
p.F55>Lfs 
 
4 
 
0 
 
0 
 
4 
 
p.P366H 
 
0 
 
0 
 
4 
 
4 
 
p.D222G 
 
0 
 
0 
 
2 
 
2 
 
c.1055delG 
 
2 
 
0 
 
0 
 
2 
 
p.R252W 
 
2 
 
0 
 
0 
 
2 
 
p.T380M 
 
0 
 
0 
 
1 
 
1 
 
p.I94S 
 
0 
 
0 
 
1 
 
1 
 
c.592_613del22 
 
1 
 
0 
 
0 
 
1 
 
p.G352fs 
 
1 
 
0 
 
0 
 
1 
 
p.G272X 
 
1 
 
0 
 
0 
 
1 
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p.P281L 
 
1 
 
0 
 
0 
 
1 
 
p.R261X 
 
1 
 
0 
 
0 
 
1 
 
p.V230I 
 
0 
 
0 
 
1 
 
1 
 
 
 
Table 7: Classification of mutations in homozygous 
patients. 
 
 
 
4.5 BH4 Responsiveness 
Our  analysis  showed  that  about  75%  of  the  analyzed 
patients are BH4-responsive mutations. The 
responsiveness to BH4 can be tested both in vivo and in 
vitro. The BH4 loading in vivo test shows BH4- 
responsiveness with a decline of L-Phe blood by more 
than 30%; a positive test indicates that the patient may 
benefit from the administration of the cofactor in 
conjunction with a diet therapy. As regards the 18 new 
mutations, 5 mutations have  been  identified  as  in vivo 
BH4 responsive while the other will have to be tested in 
the future. 
 
 
 
 
 
Fig.  18:  Representation  of  the  BH4  responsiveness  in 
PKU patients bearing novel mutation. 
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4.6 Mutations of novel identification 
In this thesis work, among the mutations identified in the 
Southern Italy population, 18 were novel, 14 are missense 
mutations, 3 are splicing mutations and one deletion. 
Moreover, all these mutations are located in regulatory 
domain, catalytic domain and tetramerization domain. The 
mutations are: 
1.  p.E76X 
2.  p.I95T 
3.  p.I65M 
4.  p.N223Y 
5.  p.Q235X 
6.  c.707-2delA 
7.  p.R297L 
8.  p.Q301P 
9.  p.L321I 
10. p.W326S 
11. p.F382L 
12. c.1199nt4A>C 
13. c.1315nt20C>T 
14. p.K328N 
15. p.N426H 
16. p.I406M 
17. p.Q419R 
18. p.T418I 
The missense mutations p.I95T, p.L321I, p.N223Y, 
p.K398N, p.F382L, p.Q419R, p.N426H, p.I1406M, p.T418I 
e p.R297L may be related to phenotype HPAIII. The 
mutation p.I65M may be associated with a severe PKU 
phenotype according to other variants of codon 65 
previously described (p.I65N, p.I65T, p.I65V and p.I65S). 
The missense mutations p.Q235X and p.Q301P, that are 
located in the cofactor binding region 4, are associated to 
severe phenotypes. Only the missense mutation p.W326S 
is associated to the intermediate phenotype HPAII, while 
the p.E76X is associated to both PKU and HPAIII. 
The c.707-2delA mutation involves the accepting splicing 
site of exon 7 causing the complete skipping of this exon. 
As a consequence of the skipping of the whole exon 7, a 
new open reading frame containing a frameshift generates 
a premature stop codon after 60 codons that leads to the 
formation of a truncated protein (p.T236MfsX60). This 
mutation, in our population, is associated to severe 
phetotype     PKU.     Finally     the     splicing     mutations 
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c.119nt4A<C E c.1315nt20C<T are associated to HPAIII 
and HPAII mild phenotype, respectively. 
 
 
 
 
4.7 Mutations identified by Next Generation Sequencing 
17 patients in which, by using direct sequencing, we did 
not identified a mutation and their parents have been 
selected for NGS and analyzed as described under 
Methods. In particular, one sequencing run was performed 
to analyze all the study population obtaining more than 
397 Mb. This was equivalent to a coverage of 100x for 
each subject, assessing the high sensitivity of our 
methodology. The high quality filtered reads were mapped 
against the human genome reference sequence to identify 
variants. NGS analysis identified mutation alterations in 9 
patients as shown in Table 8. In detail, we found in 4 
patients p.Glu178Gly mutation, in 1 patient the c.1066-11 
G>A mutation and in 1 patient the g.50448_51402del955 
deletion. Each mutation was confirmed in the patient and 
in the respective parent. In addition we identified also 3 
variants in the promoter region confirmed in the patients’ 
corresponding parent. 
 
 
 
 
Table 8: list of additional PAH mutations identified through 
NGS and the corresponding patients phenotype. 
Region  SNPs and mutations identified by NGS  
Phenotype 
 ex 6  p.Glu178Gly  HPA III 
in 10  c.1066-11G>A omo  HPA I 
in 4  g.50448_51402del955   HPA III 
ex 6  p.Glu178Gly  HPA II 
ex 6  p.Glu178Gly HPA II 
ex 6  p.Glu178Gly HPA II 
Promoter c.-30T>C HPA I 
Promoter c.-71A>C HPA III 
Promoter c.-296T>C HPA II 
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Additional data analysis are still in progress for the 
identification of other possible causative variations also in 
the remaining patients. In particular, we are developing a 
specific bioinformatic pipeline for the analysis of gene 
deletions based on sequencing coverage in different PAH 
regions. Finally, we are also deeply investigating possibly 
interesting variations in the promoter to be selected for 
further functional evaluations. 
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5. Discussion and conclusions 
The present thesis work enlarges the molecular 
epidemiology of PAH mutations, in particular, with respect 
to Southern Italy. By scanning of the PAH gene  using 
direct sequencing, we detected a mutation in 97.8% of 
chromosomes from patients affected by PKU. Complete 
genotyping   was   carried   out   in   763/780   alleles.   In 
seventeen patients only one causative mutation was 
found. 
The failure to identify a mutation in one of the 2 alleles 
may be due to: 
1) Alterations present in the promoter region or in the 
region of the 3' untranslated 
2) Molecular defects that affect introns 
3) Mutations of an enhancer 
4) Large deletions or duplications of the PAH gene 
Our study confirms the wide heterogeneity of PAH 
mutations in HPA patients also in our Campania region. 
Given the wide heterogeneity of PAH mutations, it is 
necessary to scan the whole coding region of the gene for 
molecular  analysis.  Indeed,  the  detection  rate  obtained 
with panels of exons/mutations is unsatisfactory; they 
cannot be used to plan cascade carrier screening, or for 
prenatal diagnosis, and with such a procedure some 
genotype-phenotype  correlations  may  elude  detection 
(40).  The  sequence  analysis  set-up  in  our  study  is 
sensitive and rapid, because all exons may be amplified 
under the same conditions and can be routinely used in 
reference diagnostic laboratories. 
Our study, one of the largest carried out with a specific 
ethnic group, confirms that the epidemiology of PAH 
mutations in Southern Italy differs from that in other Italian 
and  European  ethnic  groups.  For  example  p.R408W, 
which is the most frequent mutation in most ethnic groups 
(Zschocke,  2003),  has  a  frequency  <2.0%  in  Southern 
Italy. Similarly, the most frequent mutations in Northern 
Italy (p.R252W and c.1315 + 1G>A) are rare in our ethnic 
group, whereas p.R261Q, c.1066-11G>A and p.L48S are 
the most frequent PKU mutations in Campania (25). The 
epidemiology of PAH mutations in Southern and Northern 
Italy  reflects  the  pre-Roman  colonisation  of  Italy  (39): 
Celts colonized Northern Italy and most of central 
European, whereas the Greeks colonised Southern Italy, 
starting from the year 600 BC. There are also some 
differences between Southern Italian regions, i.e. Tirrenic 
(Campania) versus Adriatic (Puglia) regions, confirming 
results obtained for other genetic diseases (39). Finally, 
the most frequent mutations of our population  coincide 
with those reported in Sicilian patients (25). Unfortunately, 
the  Sicilian  study  does  not  distinguish  the  mutation 
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epidemiology within the three HPA phenotypes. In Croatia, 
Iceland, Wales and Taiwan a single mutation had a 
higher incidence (50; 10). The PAH mutations are 
differently distributed in our PKU groups of patients, 
confirming that several mutations are more frequently 
associated with the PKU phenotype and others (mainly 
missense). In particular, we confirm that p.R261Q, p.L48S 
and c.1066-11G>A are more frequently associated with 
the  PKU and mild PKU phenotypes, whereas p.A403V 
and p.E390G are peculiar to the milder phenotypes. 
Furthermore,    we    show    that    c.842+3G>C,    c.284- 
286delTCA, p.R158Q, p.E390G and p.V230I are peculiar 
to the mild HPA phenotype. Only five mutations had a 
frequency >3.0%, and the incidence of the most frequent 
mutation, i.e., p.R261Q, was 15.7%. Therefore, for few 
patients there is a discrepancy between genotype and 
phenotype. Several reasons can be attributed to this 
discrepancy: phenotypic classifications incorrect; 
combination  of  different  subunits  encoded  by  mutant 
alleles in the homotetramer protein; the action of modifier 
genes. Moreover, it must be taken into account that the 
classification on the basis of tolerance to L-Phe depends 
on both the maximum concentration of L-Phe that can be 
administered according to the age of the patient since it is 
known that the concentration of L-Phe varies with growth. 
Finally  the  phenotypic  variability  that  concerns  patients 
with the same genotype may depend on differences 
between individuals regarding the presence of molecular 
chaperons that could stabilize the mutant protein. 
In this thesis work, we identified also 18 were novel, 14 
are missense mutations, 3 are splicing mutations and 1 
deletion. Moreover, all these mutations are located in 
regulatory domain, catalytic domain and tetramerization 
domain. 12 of these are missense mutations (p.I95T, 
p.L321I, p.N223Y, p.K398N, p.F382L, p.Q419R, p.N426H, 
p.I1406M, p.T418I e p.R297L) that could be considered 
“mild”, because they are found in patients bearing a 
“severe” mutation on the second allele 
(http://www.pahdb.mcgill.ca) and showing a mild 
biochemical phenotype. Mutation p.R297L is in cis with 
p.A403V, a “mild” mutation, and in trans with p.R243X, a 
“severe”  mutation,  but  the  patient  shows  a  mild 
biochemical phenotype. Hence, p.R297L may also be 
considered a “mild” mutation. On the contrary, mutation 
p.I65M can be considered a “severe” mutation because 
the four previously described variants of codon 65 (p.I65T, 
p.I65N, p.I65V, p.I65S) are associated with a “severe” 
phenotype. Moreover, the patient bears a “mild” mutation 
on the second allele (i.e. p.A403V) and shows a mild 
phenotype. 
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The p.Q301P mutation was found in a compound 
heterozygous patient affected by an HPAII phenotype and 
bearing the p.L48S mutation on the other allele. The 
change leads to a protein with 4.4% residual enzyme 
activity  and  8–10%  residual  expression,  both  tested  in 
vitro. Two mechanisms appear to occur with this mutant 
protein: a lower stability that diminishes the protein level in 
the cell environment and a misfolding/destabilization of the 
tetrameric/dimeric structure, which impairs the catalytic 
function of the molecule. In this regard, it is noteworthy 
that Q301 is a phylogenetically highly conserved residue 
and  that no mutation has been  reported so far at this 
codon in the human PAH gene. Gln301 is located in the 
middle of an a-helix; hence, its replacement by Pro, an a- 
helix breaker residue, results in a drastic structural re- 
arrangement. Such a distortion might affect the structure 
and orientation of the Ca8 helix, which contains residues 
(i.e. R297 and Q304) anchoring a neighboring subunit, 
thereby stabilizing the dimer interface. The altered 
expression and function of the p.Q301P mutant protein 
may be attributed to destabilization of the monomer and/or 
to an altered oligomeric assembly. At the molecular level, 
the PAH tetramer may be formed from various 
combinations of mutated alleles. Homo- and 
heterotetramers can be formed at different ratios 
depending on the effects produced by mutations (i.e. 
folding defects, reduced stability or low levels of 
expression) (19). Being embodied in homo- or 
heterotetrameric proteins, the resulting enzyme may 
influence  the  overall  in  vivo  activity  (19).  In  vivo,  the 
patient bearing mutation p.Q301P presents a HPAII 
phenotype and is BH4 responsive. This phenotype may be 
attributable either to the L48S allele or to the stabilizing 
effect of BH4 on the p.Q301P monomer. Mutation p.L48S 
was shown to produce a protein in vitro that underwent 
accelerated proteolytic action, as revealed by pulse-chase 
studies (49). Interestingly, the p.R158Q and p.P281L 
mutations increase the proportion of aggregates and 
produce less PAH tetramer (24), whereas the p.R261Q 
mutation produces a well known folding defect. Residue 
R261 plays a structural role (16) in that it contributes to 
the stabilization of the tertiary structure of the catalytic 
domain through a connection of different secondary 
structure elements. 
We evaluated the biochemical phenotype in several 
patients homozygous for HPA mutations: p.P281L and 
c.1066-11G>A were associated with the PKU phenotype 
according to Bardelli’s classification (1). p.R261X and 
p.G272X were associated with the PKU phenotype, and 
p.A403V  and  p.P366H  caused  mild  HPA  (the  latter 
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mutation  was  defined  “un-  classified”  by  Bardelli  et  al. 
2002). Of the five patients carrying p.R261Q in 
homozygosity, three were affected by PKU and two by 
mild  PKU  (although  the  L-Phe  level  was  borderline 
between the clinical types). p.R261Q is known to be 
associated  with  different  phenotypes  within  the  same 
family (Kleiman et al. 1993). L-Phe levels differed widely in 
two patients carrying L48S in homozygosity, one being 
classified as “mild PKU” and the other as “mild HPA.” We 
speculate that other genes inherited independently of PAH 
may mitigate or exacerbate the biochemical genotype, as 
is the case for some Mendelian disorders (15; 41; 42). 
Furthermore, mutations in genes involved in the BH4 
pathway may cause some cases of PKU and HPA (4), but 
we ruled out such mutations in most (7 out of 10) of our 
patients with unidentified PAH mutations (data not shown). 
Large deletions of the PAH gene in heterozygosity, 
undetectable by current scanning procedures, could 
account for unknown mutations (7; 51). Furthermore, in 
other genetic diseases, sequence variations that do not 
change  amino  acids  within  the  protein  sequence  have 
been associated with impaired mRNA splicing and then as 
disease-causing mutations (37). 
Moreover,  about  75%  of  HPA  patients  from  our 
population, mainly affected by mild PKU or HPA, had 
mutations  previously  classified  as  “BH4-sensitive”  (44), 
and we identified five putative new BH4-sensitive 
mutations, which confirms that many patients may be 
treated with BH4 supplementation. BH4 sensitivity is 
usually diagnosed by the BH4 loading test, but 
identification of  the BH4-sensitive  mutation may decide 
the diagnosis in borderline cases and lead to a patient- 
rational treatment. 
In  addition,  we  performed  prenatal  diagnosis  of  three 
foetus in high-risk families; the molecular analysis of the 
PAH gene has been conducted in both parents and in 
chorionic villi or amniocytes taken at the sixteenth week of 
gestation. In one of the analyzed families, the mother of 
the foetus is affected by the HPA while the father carried 
no mutation; the foetus was a carrier of a single mutation 
and therefore not affected. In the other two families 
analyzed,  instead,  there  is  the  presence  of  another 
affected child and both parents are carriers of a single 
mutation.  One  of  the  foetus  was  affected  by  HPA  as 
carrier of both mutations in the heterozygous. The other 
foetus resulted not affected by the absence of both 
mutations of the parents. 
In conclusion, our study, has allowed us to: 
 Define correlations between some mutations and 
phenotypes of the disease. 
69 
 
 Define the responsiveness of BH4 in PKU patients. 
These  data  will  allow  patients  to  take  a  most 
appropriate therapy and personalized. 
 Define the epidemiology of mutations in PAH gene 
of patients from Southern Italy, especially in 
Campania.  These  data  may  be  useful  for 
developing kits for molecular analysis of large-scale 
HPA patients and their families 
 Calculate the residual risk to  be  carriers, and  in 
cases where it is required, to carry out prenatal 
diagnosis in cases of family history of PKU. 
 Define the differences in the epidemiology of these 
mutations, between different geographical areas. 
As additional improvement of all the other molecular 
strategies successfully applied in the present thesis, 
we developed also a NGS strategy to fully analyze the 
PAH gene including the promoter, the introns and the 
3’ UTR, for a total target of about 200 kb. 
This approach allowed the identification in one patient, 
and in his parent, of a 955 bp deletion causing the 
skipping of the exon 5. In other 4 patients we identified, 
as second causative mutation, the p.Glu178Gly 
mutation. Finally, other interesting variants in PAH 
regulatory regions are still under evaluation. In 
particular, 3 interesting variants in the promoter region 
have been identified and, given their possible 
pathogenetic role, selected for further functional 
evaluations. 
Totally, by using this novel approach, we were able to 
additionally increase our diagnostic sensitivity 
ameliorating the mutation detection rate to a value of 
98.8%. 
These data may help to reconstruct the historical and 
anthropological point of view, the various settlements 
that have occurred in our country. 
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BACKGROUND.  Phenylketonuria  (PKU)   is   the   most   important 
disorder of amino acid metabolism, resulting mainly from a deficiency 
of phenylalanine hydroxylase (PAH) that metabolises phenylalanine to 
tyrosine. Usually, defective PAH activity is caused by mutations in the 
PAH gene; more than 500 mutations, scattered over the entire gene 
length, having been reported to date. Mutation analysis is important to 
obtain information on expected phenotype, for family counseling, to 
identify PKU carriers and for prenatal diagnosis. The scanning of PAH 
gene by direct sequencing detected a mutation in 90% of patients. 
Therefore, this strategy failed to reveal a point mutation or 
deletion/insertion on several alleles. 
In this study, we developed and tested a method for the 
comprehensive and sensitive detection of PAH mutations using long- 
range (LR) PCR and next generation sequencing. 
METHODS. The study was carried out on 19 PKU patients for which 
the conventional Sanger exons screening was able to detect only one 
causative mutation. DNA samples of patient’s parents were also 
available for molecular testing and results confirmation. Sixteen LR- 
PCR fragments, between 3,400 and 11,700 bp, containing the 
promoter, all coding exons, all introns and the 3’ UTR of PAH were 
individually obtained for each study subject. The purified amplicons of 
the same patient were then pooled in equimolar ratio to obtain a 
library/sample.  The  libraries  were  sequenced  with  the  GS  FLX 
System. Sequence and data analysis was performed using the 
Roche/454 gsMapper software. 
RESULTS. All LR-PCR fragments were completely sequenced. We 
detected and confirmed 100% of the mutations and SNP previously 
identified in the same samples by Sanger analysis. In addition, we 
identified  some  interesting  possibly  pathogenetic  variations  that 
segregated with the family inheritance (40% of the studied subjects). 
CONCLUSION. Our results demonstrates that genomic LR-PCR and 
next  generation  sequencing,  increasing  diagnostic  sensitivity,  can 
provide   comprehensive genetic   information   more   quickly   and 
accurately than conventional approaches, being an effective method 
for patient sample analysis of PAH gene. 
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La  Fenilchetonuria (PKU)  e  le  sue  varianti,  le  Iperfenilalaninemie 
(HPA) derivano dalla deficienza della fenilalanina idrossilasi (PAH: EC 
1.14.16.1), enzima epatico che utilizza la tetraidrobiopterina (BH4) per 
metabolizzare la Fenilalanina (Phe) in Tirosina (Tyr). Gli alti livelli di 
Phe e dei suoi metaboliti sono neurotossici e determinano gravi danni 
cerebrali. Recentemente è stato osservato che un trattamento 
aggiuntivo con BH4 rappresenta in alcuni pazienti un valido 
trattamento. Il gene PAH mappa sul cromosoma 12q23.2 codifica per 
una  proteina  di  50kDa  costituita  da  un  dominio  regolatorio,  uno 
catalitico e uno di tetramerizzazione. Nel 97% delle forme di HPA, 
l'attività PAH difettiva è causata da mutazioni nel gene PAH; sono 
state identificate più di 500 mutazioni la maggior parte delle quali 
distribuite sull'intera lunghezza del gene (http://www.pahdb.mcgill.ca). 
L'identificazione delle mutazioni è utile per ottenere informazioni sia 
sul fenotipo del paziente sia sulla proteina e per poter svolgere una 
più completa consulenza genetica nelle famiglie a rischio; inoltre la 
diagnosi  molecolare  permette  l'identificazione dei  portatori  sani  di 
HPA   e   l'esecuzione  di   diagnosi  prenatali.  L'analisi  molecolare 
permette inoltre una migliore classificazione dei pazienti responsivi al 
BH4  permettendo  un  approccio  terapeutico  più  personalizzato  e 
quindi più appropriato. La procedura attualmente utilizzata si basa sul 
sequenziamento diretto, mediante metodo Sanger del promotore e dei 
13 esoni del gene PAH. Con questa strategia di analisi abbiamo 
identificato mutazioni in più 90% dei pazienti per cui sarebbe 
auspicabile mettere a punto una procedura di analisi più sensibile che 
permetta di identificare anche delezioni che coprono uno o più esoni e 
che risultano difficilmente riconoscibili negli eterozigoti compositi a 
causa dell'effetto mascherante dell'allele non deleto. L'obiettivo di 
questo studio è mettere a punto una nuova e più sensibile strategia di 
analisi delle mutazioni mediante approccio di high-throughput 
sequencing GS FLX. Materiali e metodi: Abbiamo raccolto campioni di 
sangue (3 ml) in EDTA ed estratto il DNA di soggetti sani e di pazienti 
affetti da PKU identificati dallo screening neonatale. Utilizzando il 
software Primer3, abbiamo disegnato primers specifici per amplificare 
e analizzare regioni di 100 kb che comprendessero 20 Kb nella 
regione del promotore, tutti gli esoni ed introni, 5 kb della regione 3 
'UTR del gene PAH. Risultati: Utilizzando un protocollo di PCR touch- 
down, abbiamo generato lunghi ampliconi parzialmente sovrapposti, 
le cui dimensioni variano tra i 8-12 Kb. Ciascun amplicone è stato poi 
amplificato   e   purificato.   Dopo   valutazione   della   qualità   (2100 
Bioanalyzer, Agilent) e quantificazione (Picogreen test, Invitrogen), i 
prodotti di amplificazione da uno stesso campione di DNA sono stati 
sequenziati. Conclusioni: l'approccio di amplificazione tramite PCR e 
sequenziamento highthroughput è in grado di rilevare sia alterazioni di 
singoli nucleotidi sia grosse delezioni o duplicazioni nei geni target 
aumentando così lo spettro delle alterazioni genetiche rilevabili e di 
conseguenza la detection rate. 
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Introduction: Phenylketonuria (OMIM 261600) is the most common 
disorder of amino acid metabolism caused by phenylalanine 
hydroxylase (PAH: EC 1.14.16.1) deficiency. Accumulation of Phe 
causes severe brain damage with mental retardation but an early Phe- 
restricted diet prevents neurocognitive and developmental damage. In 
PKU, defective PAH activity results from mutations in the PAH gene. 
To date, more than 600 mutations have been identified 
(http://www.pahdb.mcgill.ca). Mutation analysis is important to obtain 
information both about the expected phenotype and for genetic 
counseling. In our lab, we perform the molecular diagnosis of HPA 
with a detection rate of ∼90% (Daniele, 2008; Daniele 2011). Our aim 
is to set-up a new and more sensitive strategy using high-throughput 
sequencing approach. 
Materials and Methods: From controls and PKU patients identified 
from neonatal screening, we collected a blood sample (3 mL) in EDTA 
and extracted DNA using a standard protocol. Using the Primer3 
software (http://frodo.wi.mit.edu/primer3/), we designed specific 
primers encompassing about 100 kb including 20 kb of the promoter 
region, all exons and introns, and 5 kb of the 3’ UTR region of PAH 
gene. 
Results: Overlapping long-PCR amplicons, ranging in size between 8- 
12 kb, were generated using a “touch-down” PCR protocol. Each 
amplicon was individually amplified and purified. After appropriate 
quality assessment (2100 BioAnalyzer, Agilent) and quantification 
(Picogreen assay, Invitrogen), the amplification products from the 
same DNA sample are sequenced. 
Conclusions: The PCR amplification/high throughput sequencing 
approach detects both single-nucleotide polymorphisms and CNVs in 
target genes thereby increasing the spectrum of detected variations 
within the analyzed gene. 
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Introduzione: Le Iperfenilalaninemie derivano dalla deficienza della 
fenilalanina idrossilasi (PAH) che converte la Fenilalanina in Tirosina. 
Alti livelli di fenilalanina sono neurotossici e determinano gravi danni 
cerebrali. Il gene PAH codifica una proteina di 50kDa costituita da un 
dominio regolatorio, uno catalitico, uno di tetramerizzazione. Nel 97% 
dei pazienti, l’attività PAH difettiva è causata da mutazioni nel gene 
PAH (http://www.pahdb.mcgill.ca). L’identificazione delle mutazioni è 
utile per ottenere informazioni sia sul fenotipo del paziente, sia sulla 
proteina, e per una più completa consulenza genetica; inoltre, la 
diagnosi molecolare permette l’identificazione dei portatori sani e la 
diagnosi prenatale. Scopo: mettere a punto una procedura di analisi 
più sensibile che permetta di identificare mutazioni nel 99% dei 
pazienti. 
Metodi: Il gene PAH è stato amplificato mediante Long-PCR. Ciascun 
amplicone   è   stato   purificato   ed   analizzato   per   qualità   (2100 
BioAnalyzer, Agilent) e quantità (Picogreen assay, Invitrogen). Gli 
ampliconi dello stesso paziente sono stati assemblati in rapporto 
equimolare ed utilizzati per generare librerie da sequenziare mediante 
sequenziamento high throughput (GS FLX System). 
Risultati: Specifici primer sono stati disegnati con il software Primer3 
(http://frodo.wi.mit.edu/primer3/) e le condizioni di amplificazione sono 
state  ottimizzate.  Il  DNA  di  tutti  i  pazienti  selezionati  è  stato 
amplificato in modo da ottenere un pool di ampliconi per ciascun 
paziente. E’ in corso la preparazione delle librerie per il 
sequenziamento. 
Conclusioni: questo nuovo approccio permette l’identificazione delle 
mutazioni nel gene PAH, compreso il promotore, le regioni codificanti 
e non codificanti. In questo modo, saranno identificati variazioni 
nucleotidiche, delezioni/inserzioni e polimorfismi ad oggi non descritti. 
Questo approccio permetterà di analizzare simultaneamente diversi 
pazienti   riducendo   in   maniera   significativa   i   tempi   dell’analisi. 
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La  Fenilchetonuria  (PKU)  è  una  patologia  autosomica  recessiva 
legata nel 98% dei casi a mutazioni del gene Fenilalanina idrossilasi 
(PAH). Il gene PAH codifica per un enzima ad espressione epatica 
che catalizza la trasformazione della Fenilalanina (Phe) in Tirosina in 
presenza  di  O2  e  Tetraidrobiopterina  (BH4).  La  ridotta  attività 
dell enzima comporta un incremento delle concentrazioni plasmatiche 
di Phe che determinano gravi danni cerebrali se la PKU non è 
tempestivamente diagnosticata e trattata. Mutazioni nel gene PAH 
causano mancata o ridotta attività dell'enzima; attraverso l'analisi 
molecolare del gene PAH si effettua la diagnosi genetica di PKU. 
Elevati livelli plasmatici di Phe durante la gravidanza esercitano effetti 
teratogeni sul feto e creano una condizione di Iperfenilalaninemia 
embrio-fetale, lesiva della morfogenesi, nonch   dello sviluppo fisico e 
cerebrale del prodotto del concepimento che va sotto il nome di 
sindrome da PKU materna (MSPKU). Il 95% dei neonati affetti da 
MSPKU presentano ritardo mentale, il 73% microcefalia, il 40% ritardo 
di crescita intrauterino e il 12% difetti congeniti cardiaci. Sono state 
ipotizzate correlazioni tra il genotipo PKU, il fenotipo biochimico e 
quello clinico. Nella patogenesi della MSPKU è stata suggerita 
un'implicazione della barriera emato-encefalica, in particolare del 
sistema LNAA (large neutral amino acid transporter 1, LAT1), 
responsabile del  trasporto  della  Phe.  Alterazioni nucleotidiche nel 
gene codificante LAT1, quindi, potrebbero giocare un ruolo nel 
determinare una diversa suscettibilità ai danni cerebrali in pazienti 
affetti da MSPKU. In questo studio riportiamo un caso di MSPKU; si 
tratta di un neonato partorito da una paziente affetta dalla forma grave 
di PKU; essa infatti presenta livelli di Phe superiori ai 1200 umol/l. La 
paziente  PKU  è  arrivata  al  Centro  di  Screening  per  la  PKU 
dell Ospedale SS. Annunziata di Napoli in stato di gravidanza. La 
paziente, nonostante il counselling genetico, non ha effettuato 
dietoterapia e il neonato è risultato affetto da MSPKU classica (grave 
microcefalia, difetti cardiaci). Abbiamo effettuato in questa paziente 
l'analisi molecolare del gene PAH evidenziando la presenza di due 
mutazioni riportate nel database delle mutazioni causative di PKU: 
c.1066-11G A e p.L48S. La prima mutazione si trova nel sito attivo 
dell enzima, in particolare nel dominio di legame al suo cofattore BH4 
e si associa sempre a fenotipo grave. La seconda mutazione, che 
cade nel dominio di autoregolazione della proteina, è associata a tutti i 
fenotipi di Fenilchetonuria. Abbiamo effettuato inoltre l'analisi 
molecolare del gene PAH nel neonato PKU evidenziando la presenza 
della mutazione p.L48S in eterozigosi. Inoltre abbiamo messo a punto 
la procedura per effettuare il sequenziamento del gene LAT1. 
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Phenylketonuria (OMIM database: 261600) and its 
Hyperphenylalaninemia (HPA) variants are the most important 
disorders of amino acid metabolism caused by a deficiency of 
phenylalanine hydroxylase (PAH: EC 1.14.16.1), which metabolizes 
phenylalanine (Phe) to tyrosine. Phe causes severe brain damage but 
an early Phe-restricted diet prevents neurocognitive and 
developmental damage. In most HPA forms, defective PAH activity 
results from mutations in the PAH gene. To date, more than 500 
mutations, scattered throughout the gene, have been identified 
(http://www.pahdb.mcgill.ca). Mutation analysis is important to obtain 
information both about the expected phenotype and for counseling in 
the affected families. In our lab, we perform the molecular diagnosis of 
HPA  with  a  detection  rate  of  90%  [1,  2].    We  have  set-up  a 
competitive strategy based on the high-throughput sequencing 
approach. From a control population and HPA patients identified from 
neonatal screening, we collected a blood sample (3 mL) in EDTA and 
extracted DNA using a standard protocol. Using the Primer3 software 
(http://frodo.wi.mit.edu/primer3/), we designed specific primers 
encompassing about 100 kb including 20 kb of the promoter region, all 
exons and introns, and 5 kb of the 3’ UTR region of PAH gene. 
Subsequently, overlapping long-PCR amplicons, ranging in size 
between  8-12  kb,  were  generated using  a  “touch-down” protocol. 
Each amplicon was individually amplified and purified. After 
appropriate quality assessment (2100 BioAnalyzer, Agilent) and 
quantification (Picogreen assay, Invitrogen), the amplification products 
from the same DNA sample are sequenced. The PCR 
amplification/high throughput sequencing approach detects both 
single-nucleotide polymorphisms and CNVs in target genes thereby 
increasing the spectrum of detected variations within the analyzed 
gene. 
1. Daniele A et al. (2008) BBA, 1782, 378 
2. Daniele A et al. (2009) FEBS Journal 276, 2048 
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La  Fenilchetonuria (PKU)  e  le  sue  varianti,  le  Iperfenilalaninemie 
(HPA) derivano dalla deficienza della fenilalanina idrossilasi (PAH: EC 
1.14.16.1), enzima epatico che utilizza la tetraidrobiopterina (BH4) per 
metabolizzare la Fenilalanina (Phe) in Tirosina (Tyr). Gli alti livelli di 
Phe e dei suoi metaboliti sono neurotossici e determinano gravi danni 
cerebrali. Recentemente è stato osservato che un trattamento 
aggiuntivo con BH4 rappresenta in alcuni pazienti un valido 
trattamento. Il gene PAH mappa sul cromosoma 12q23.2 codifica per 
una proteina di 50kDa costituita da un dominio regolatorio, uno 
catalitico e uno di tetramerizzazione. Nel 97% delle forme di HPA, 
l attività PAH difettiva è causata da mutazioni nel gene PAH; sono 
state identificate pi   di 500 mutazioni la maggior parte delle quali 
distribuite sull'intera lunghezza del gene (http://www.pahdb.mcgill.ca) 
(1). L identificazione delle mutazioni è utile per ottenere informazioni 
sia sul fenotipo del paziente sia sulla proteina e per poter svolgere 
una pi   completa consulenza genetica nelle famiglie a rischio; inoltre 
la diagnosi molecolare permette l'identificazione dei portatori sani di 
HPA  e   l esecuzione  di   diagnosi   prenatali.   L analisi  molecolare 
permette inoltre una migliore classificazione dei pazienti responsivi al 
BH4  permettendo  un  approccio  terapeutico  pi    personalizzato  e 
quindi pi   appropriato. La procedura attualmente utilizzata si basa sul 
sequenziamento diretto, mediante metodo Sanger del promotore e dei 
13 esoni del gene PAH. Con questa strategia di analisi abbiamo 
identificato le mutazioni in pi   90% dei pazienti (2) per cui sarebbe 
auspicabile mettere a punto una procedura di analisi pi   sensibile che 
permetta di identificare anche delezioni che coprono uno o pi   esoni e 
che risultano difficilmente riconoscibili negli eterozigoti compositi a 
causa dell'effetto mascherante dell'allele non deleto. In questo lavoro, 
abbiamo intenzione di sequenziare mediante il sistema high- 
throughput GS FLX l'intero gene PAH e di identificare in modo 
altamente accurato e a costi sostenibili le mutazioni presenti sia nelle 
regioni esoniche, sia in quelle introniche e sia nelle regioni del 
promotore del gene PAH; in pi   utilizzando questa strategia di analisi 
potranno essere identificate in modo accurato anche delezioni e/o 
inserzioni geniche. In questo modo, saremo in grado di evidenziare 
variazioni nucleotidiche e/o genomiche presenti negli alleli in cui non è 
stato  possibile  identificare  mutazioni  mediante  lo  screening 
tradizionale aumentando la detection rate dell'analisi molecolare di 
HPA. 
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